

A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids

Shweta Ramdas^{1*}, Jonathan Judd^{2*}, Sarah E Graham^{3*}, Stavroula Kanoni^{4*}, Yuxuan Wang^{5*}, Ida Surakka³, Brandon Wenz¹, Shoa L Clarke^{6,7}, Alessandra Chesi⁸, Andrew Wells¹, Konain Fatima Bhatti⁴, Sailaja Vedantam^{9,10}, Thomas W Winkler¹¹, Adam E Locke¹², Eirini Marouli⁴, Greg JM Zajac¹³, Kuan-Han H Wu¹⁴, Ioanna Ntalla¹⁵, Qin Hui^{16,17}, Derek Klarin^{18,19,20}, Austin T Hilliard⁶, Zeyuan Wang^{16,17}, Chao Xue³, Gudmar Thorleifsson²¹, Anna Helgadottir²¹, Daniel F Gudbjartsson^{21,22}, Hilma Holm²¹, Isleifur Olafsson²³, Mi Yeong Hwang²⁴, Sohee Han²⁴, Masato Akiyama^{25,26}, Saori Sakaue^{27,28,29}, Chikashi Terao³⁰, Masahiro Kanai^{25,31,32}, Wei Zhou^{33,14,20}, Ben M Brumpton^{34,35,36}, Humaira Rasheed^{34,35,37}, Aki S Havulinna^{38,39}, Yogasudha Veturi⁴⁰, Jennifer Allen Pacheco⁴¹, Elisabeth A Rosenthal⁴², Todd Lingren⁴³, QiPing Feng⁴⁴, Iftikhar J. Kullo⁴⁵, Akira Narita⁴⁶, Jun Takayama⁴⁶, Hilary C Martin⁴⁷, Karen A Hunt⁴⁸, Bhavi Trivedi⁴⁸, Jeffrey Haessler⁴⁹, Franco Giulianini⁵⁰, Yuki Bradford⁴⁰, Jason E Miller⁴⁰, Archie Campbell^{51,52}, Kuang Lin⁵³, Iona Y Millwood^{53,54}, Asif Rasheed⁵⁵, George Hindy⁵⁶, Jessica D Faul⁵⁷, Wei Zhao⁵⁸, David R Weir⁵⁷, Constance Turman⁵⁹, Hongyan Huang⁵⁹, Mariaelisa Graff⁶⁰, Ananyo Choudhury⁶¹, Dhriti Sengupta⁶¹, Anubha Mahajan⁶², Michael R Brown⁶³, Weihua Zhang^{64,65,66}, Ketian Yu¹³, Ellen M Schmidt¹³, Anita Pandit¹³, Stefan Gustafsson⁶⁷, Xianyong Yin¹³, Jian'an Luan⁶⁸, Jing-Hua Zhao⁶⁹, Fumihiko Matsuda⁷⁰, Hye-Mi Jang²⁴, Kyunghoon Yoon²⁴, Carolina Medina-Gomez⁷¹, Achilleas Pitsillides⁵, Jouke Jan Hottenga^{72,73}, Andrew R Wood⁷⁴, Yingji Ji⁷⁴, Zishan Gao^{75,76,77}, Simon Haworth^{35,78}, Ruth E Mitchell^{35,79}, Jin Fang Chai⁸⁰, Mette Aadahl^{81,82}, Anne A Bjerregaard⁸¹, Jie Yao⁸³, Ani Manichaikul⁸⁴, PhD Wen-Jane⁸⁵, PhD Chao A⁸⁶, Helen R Warren^{87,88}, Julia Ramirez⁸⁷, Jette Bork-Jensen⁸⁹, Line L Kårhus⁸¹, Anuj Goel^{90,91}, Maria Sabater-Lleal^{92,93}, Raymond Noordam⁹⁴, Pala Mauro⁹⁵, Floris Matteo^{96,95}, Aaron F McDaid^{97,98}, Pedro Marques-Vidal⁹⁹, Matthias Wielscher¹⁰⁰, Stella Trompet^{101,102}, Naveed Sattar¹⁰³, Line T Møllehave⁸¹, Matthias Munz¹⁰⁴, Lingyao Zeng^{105,106}, Jianfeng Huang¹⁰⁷, Bin Yang¹⁰⁷, Alaitz Poveda¹⁰⁸, Azra Kurbasic¹⁰⁸,

26 Sebastian Schönherr¹⁰⁹, Lukas Forer¹⁰⁹, Markus Scholz^{110,111}, Tessel E. Galesloot¹¹², Jonathan P.
 27 Bradfield¹¹³, Sanni E Ruotsalainen³⁸, E Warwick Daw¹¹⁴, Joseph M Zmuda¹¹⁵, Jonathan S
 28 Mitchell¹¹⁶, Christian Fuchsberger¹¹⁶, Henry Christensen¹¹⁷, Jennifer A Brody¹¹⁸, Phuong Le^{119,120},
 29 Mary F Feitosa¹¹⁴, Mary K Wojczynski¹¹⁴, Daiane Hemerich¹²¹, Michael Preuss¹²¹, Massimo
 30 Mangino^{122,123}, Paraskevi Christofidou¹²², Niek Verweij¹²⁴, Jan W Benjamins¹²⁴, Jorgen
 31 Engmann^{125,126}, Tsao L. Noah¹²⁷, Anurag Verma¹²⁸, Roderick C Sliker^{128,129}, Ken Sin Lo¹³⁰, Nuno R
 32 Zilhao¹³¹, Marcus E Kleber^{132,133}, Graciela E Delgado¹³², Shaofeng Huo¹³⁴, Daisuke D Ikeda¹³⁵,
 33 Hiroyuki Iha¹³⁵, Jian Yang^{136,137,138}, Jun Liu^{139,140}, Ayşe Demirkan^{141,142}, Hampton L Leonard^{143,144},
 34 Jonathan Marten¹⁴⁵, Carina Emmel¹⁴⁶, Borge Schmidt¹⁴⁶, Laura J Smyth¹⁴⁷, Marisa Cañadas-
 35 Garre^{147,148,149,150}, Chaolong Wang^{151,152}, Masahiro Nakatochi¹⁵³, Andrew Wong¹⁵⁴, Nina Hutri-
 36 Kähönen¹⁵⁵, Xueling Sim⁸⁰, Rui Xia¹⁵⁶, Alicia Huerta-Chagoya¹⁵⁷, Juan Carlos Fernandez-
 37 Lopez¹⁵⁸, Valeriya Lyssenko^{159,160}, Suraj S Nongmaithem¹⁶¹, Alagu Sankareswaran^{161,162},
 38 Marguerite R Irvin¹⁵⁴, Christopher Oldmeadow¹⁶³, Han-Na Kim^{164,165}, Seunggho Ryu^{166,167}, Paul RHJ
 39 Timmers^{168,145}, Liubov Arbeeveva¹⁶⁹, Rajkumar Dorajoo^{152,170}, Leslie A Lange¹⁷¹, Gauri Prasad^{172,173},
 40 Laura Lorés-Motta¹⁷⁴, Marc Pauper¹⁷⁴, Jirong Long¹⁷⁵, Xiaohui Li⁸³, Elizabeth Theusch¹⁷⁶,
 41 Fumihiko Takeuchi¹⁷⁷, Cassandra N Spracklen^{178,179}, Anu Loukola³⁸, Sailalitha Bollepalli³⁸,
 42 Sophie C Warner^{180,181}, Ya Xing Wang¹⁸², Wen B. Wei¹⁸³, Teresa Nutile¹⁸⁴, Daniela Ruggiero^{184,185},
 43 Yun Ju Sung¹⁸⁶, Shufeng Chen¹⁰⁷, Fangchao Liu¹⁰⁷, Jingyun Yang^{187,188}, Katherine A Kentistou¹⁶⁸,
 44 Bernhard Banas¹⁸⁹, Anna Morgan¹⁹⁰, Karina Meidtner^{191,192}, Lawrence F Bielak⁵⁸, Jennifer A
 45 Smith^{58,57}, Prashantha Hebbar¹⁹³, Aliko-Eleni Farmaki^{194,195}, Edith Hofer^{196,197}, Maoxuan Lin¹⁹⁸, Maria
 46 Pina Concas¹⁹⁹, Simona Vaccargiu²⁰⁰, Peter J van der Most²⁰¹, Niina Pitkänen^{202,203}, Brian E
 47 Cade^{204,205}, Sander W. van der Laan²⁰⁶, Kumaraswamy Naidu Chitralla^{207,208}, Stefan Weiss²⁰⁹, Amy
 48 R Bentley²¹⁰, Ayo P Doumatey²¹⁰, Adebawale A Adeyemo²¹⁰, Jong Young Lee²¹¹, Eva RB
 49 Petersen²¹², Aneta A Nielsen²¹³, Hyeok Sun Choi²¹⁴, Maria Nethander^{215,216}, Sandra Freitag-Wolf²¹⁷,
 50 Lorraine Southam^{218,47}, Nigel W Rayner^{219,220,47,218}, Carol A Wang²²¹, Shih-Yi Lin^{222,223,224}, Jun-Sing

51 Wang^{225,226}, Christian Couture²²⁷, Leo-Pekka Lyytikäinen^{228,229}, Kjell Nikus^{230,231}, Gabriel Cuellar-
 52 Partida²³², Henrik Vestergaard^{89,233}, Bertha Hidalgo²³⁴, Olga Giannakopoulou⁴, Qiuyin Cai¹⁷⁵,
 53 Morgan O Obura¹²⁸, Jessica van Setten²³⁵, Karen Y. He²³⁶, Hua Tang²³⁷, Natalie Terzikhan²³⁸, Jae
 54 Hun Shin²¹⁴, Rebecca D Jackson²³⁹, Alexander P Reiner²⁴⁰, Lisa Warsinger Martin²⁴¹, Zhengming
 55 Chen^{53,54}, Liming Li²⁴², Takahisa Kawaguchi⁷⁰, Joachim Thiery^{243,111}, Joshua C Bis¹¹⁸, Lenore J
 56 Launer²⁴⁴, Huaixing Li²⁴⁵, Mike A Nalls^{143,144}, Olli T Raitakari^{246,247,248}, Sahoko Ichihara²⁴⁹, Sarah H
 57 Wild²⁵⁰, Christopher P Nelson^{180,181}, Harry Campbell¹⁶⁸, Susanne Jäger^{191,192}, Toru Nabika²⁵¹, Fahd
 58 Al-Mulla¹⁹³, Harri Niinikoski^{252,253}, Peter S Braund^{180,181}, Ivana Kolcic²⁵⁴, Peter Kovacs²⁵⁵, Tota
 59 Giardoglou²⁵⁶, Tomohiro Katsuya^{257,258}, Dominique de Kleijn²⁵⁹, Gert J. de Borst²⁵⁹, Eung Kweon
 60 Kim²⁶⁰, Hieab H.H. Adams^{238,261}, M. Arfan Ikram²³⁸, Xiaofeng Zhu²³⁶, Folkert W Asselbergs²³⁵,
 61 Adriaan O Kraaijeveld²³⁵, Joline WJ Beulens^{128,262}, Xiao-Ou Shu¹⁷⁵, Loukianos S Rallidis²⁶³, Oluf
 62 Pedersen⁸⁹, Torben Hansen⁸⁹, Paul Mitchell²⁶⁴, Alex W Hewitt^{265,266}, Mika Kähönen^{267,268}, Louis
 63 Pérusse^{227,269}, Claude Bouchard²⁷⁰, Anke Tönjes²⁷¹, Yii-Der Ida Chen⁸³, Craig E Pennell²²¹, Trevor
 64 A Mori²⁷², Wolfgang Lieb²⁷³, Andre Franke²⁷⁴, Claes Ohlsson^{215,275}, Dan Mellström^{215,276}, Yoon Shin
 65 Cho²¹⁴, Hyejin Lee²⁷⁷, Jian-Min Yuan^{278,279}, Woon-Puay Koh^{280,281}, Sang Youl Rhee²⁸², Jeong-Taek
 66 Woo²⁸², Iris M Heid¹¹, Klaus J Stark¹¹, Martina E Zimmermann¹¹, Henry Völzke²⁸³, Georg
 67 Homuth²⁰⁹, Michele K Evans²⁸⁴, Alan B Zonderman²⁸⁴, Ozren Polasek^{254,285}, Gerard Pasterkamp²⁰⁶,
 68 Imo E Hoefer²⁰⁶, Susan Redline^{204,205}, Katja Pahkala^{202,203,286}, Albertine J Oldehinkel²⁸⁷, Harold
 69 Snieder²⁰¹, Ginevra Biino²⁸⁸, Reinhold Schmidt¹⁹⁶, Helena Schmidt²⁸⁹, Stefania Bandinelli²⁹⁰,
 70 George Dedoussis¹⁹⁴, Thangavel Alphonse Thanaraj¹⁹³, Patricia A Peyser⁵⁸, Norihiro Kato¹⁷⁷,
 71 Matthias B Schulze^{191,192,291}, Giorgia Grotto^{292,199}, Carsten A Böger^{189,293,294}, Bettina Jung^{189,293,294}, Peter
 72 K Joshi¹⁶⁸, David A Bennett^{187,188}, Philip L De Jager^{295,296}, Xiangfeng Lu¹⁰⁷, Vasiliki Mamakou^{297,298},
 73 Morris Brown^{299,88}, Mark J Caulfield^{87,88}, Patricia B Munroe^{87,88}, Xiuqing Guo⁸³, Marina Ciullo^{184,185},
 74 Jost B. Jonas^{300,182,301,302}, Nilesh J Samani^{180,181}, Jaakko Kaprio³⁸, Päivi Pajukanta³⁰³, Teresa Tusié-
 75 Luna^{304,305}, Carlos A Aguilar-Salinas³⁰⁶, Linda S Adair^{307,308}, Sonny Augustin Bechayda^{309,310}, H.

76 Janaka de Silva³¹¹, Ananda R Wickremasinghe³¹², Ronald M Krauss³¹³, Jer-Yuarn Wu³¹⁴, Wei
 77 Zheng¹⁷⁵, Anneke I den Hollander¹⁷⁴, Dwaipayan Bharadwaj^{173,315}, Adolfo Correa³¹⁶, James G
 78 Wilson³¹⁷, Lars Lind³¹⁸, Chew-Kiat Heng³¹⁹, Amanda E Nelson^{169,320}, Yvonne M Golightly^{169,321,322,323},
 79 James F Wilson^{168,145}, Brenda Penninx^{324,325}, Hyung-Lae Kim³²⁶, John Attia^{327,163}, Rodney J Scott^{327,163},
 80 D C Rao³²⁸, Donna K Arnett³²⁹, Mark Walker³³⁰, Laura J Scott¹³, Heikki A Koistinen^{39,331,332}, Giriraj
 81 R Chandak^{161,162,333}, Josep M Mercader^{334,335,336}, Teresa Tusie-Luna³³⁷, Carlos Aguilar-Salinas³³⁸,
 82 Clicerio Gonzalez Villalpando³³⁹, Lorena Orozco³⁴⁰, Myriam Fornage^{156,341}, E Shyong Tai^{342,80}, Rob
 83 M van Dam^{80,342}, Terho Lehtimäki^{228,229}, Nish Chaturvedi³⁴³, Mitsuhiro Yokota³⁴⁴, Jianjun Liu¹⁵²,
 84 Dermot F Reilly³⁴⁵, Amy Jayne McKnight¹⁴⁷, Frank Kee¹⁴⁷, Karl-Heinz Jöckel¹⁴⁶, Mark I
 85 McCarthy^{62,346}, Colin NA Palmer³⁴⁷, Veronique Vitart¹⁴⁵, Caroline Hayward¹⁴⁵, Eleanor
 86 Simonsick³⁴⁸, Cornelia M van Duijn^{139,140}, Zi-Bing Jin^{349,350}, Fan Lu³⁵⁰, Haretsugu Hishigaki¹³⁵, Xu
 87 Lin¹³⁴, Winfried März^{351,352,132}, Vilmundur Gudnason^{131,353}, Jean-Claude Tardif¹³⁰, Guillaume
 88 Lettre¹³⁰, Leen M t Hart^{354,355,356}, Petra JM Elders³⁵⁷, Daniel J Rader³⁵⁸, Scott M Damrauer^{359,360},
 89 Meena Kumari³⁶¹, Mika Kivimäki¹²⁶, Pim van der Harst³⁶², Tim D Spector¹²², Ruth J.F. Loos^{121,363,89},
 90 Michael A Province¹¹⁴, Esteban J Parra¹¹⁹, Miguel Cruz³⁶⁴, Bruce M Psaty^{118,365,366}, Ivan
 91 Brandslund^{117,367}, Peter P Pramstaller¹¹⁶, Charles N Rotimi³⁶⁸, Kaare Christensen³⁶⁹, Samuli
 92 Ripatti^{38,370,371}, Elisabeth Widén³⁸, Hakon Hakonarson^{372,373}, Struan F.A. Grant^{373,374,375}, Lambertus
 93 ALM Kiemeny³⁷⁶, Jacqueline de Graaf³⁷⁶, Markus Loeffler^{110,111}, Florian Kronenberg¹⁰⁹,
 94 Dongfeng Gu^{107,377}, Jeanette Erdmann³⁷⁸, Heribert Schunkert^{105,106}, Paul W Franks¹⁰⁸, Allan
 95 Linneberg^{81,82}, J. Wouter Jukema^{101,379}, Amit V Khera^{380,381,382,383}, Minna Männikkö³⁸⁴, Marjo-Riitta
 96 Jarvelin^{100,385,386}, Zoltan Kutalik^{97,98}, Cucca Francesco^{387,388}, Dennis O Mook-Kanamori^{389,390}, Ko
 97 Willems van Dijk^{391,392,393}, Hugh Watkins^{90,91}, David P Strachan³⁹⁴, Niels Grarup⁸⁹, Peter Sever³⁹⁵,
 98 Neil Poulter³⁹⁶, Wayne Huey-Herng Sheu^{397,398}, Jerome I Rotter⁸³, Thomas M Dantoft⁸¹, Fredrik
 99 Karpe^{399,400}, Matt J Neville^{399,400}, Nicholas J Timpson^{35,79}, Ching-Yu Cheng^{401,402}, Tien-Yin Wong^{401,402},
 100 Chiea Chuen Khor¹⁵², Hengtong Li⁴⁰³, Charumathi Sabanayagam^{401,402}, Annette Peters^{77,404,405},

101 Christian Gieger^{76,77,405}, Andrew T Hattersley⁴⁰⁶, Nancy L Pedersen⁴⁰⁷, Patrik KE Magnusson⁴⁰⁷,
 102 Dorret I Boomsma^{72,408}, Eco JC de Geus^{72,408}, L Adrienne Cupples^{5,409}, Joyce B.J. van Meurs^{71,140},
 103 Arfan Ikram¹⁴⁰, Mohsen Ghanbari^{140,410}, Penny Gordon-Larsen^{307,308}, Wei Huang⁴¹¹, Young Jin
 104 Kim²⁴, Yasuharu Tabara⁷⁰, Nicholas J Wareham⁶⁸, Claudia Langenberg⁶⁸, Eleftheria
 105 Zeggini^{218,47,412}, Jaakko Tuomilehto^{39,413,414}, Johanna Kuusisto⁴¹⁵, Markku Laakso⁴¹⁵, Erik
 106 Ingelsson^{7,416,417,418}, Goncalo Abecasis^{13,419}, John C Chambers^{420,64,65,421}, Jaspal S Kooner^{65,66,422,423}, Paul S
 107 de Vries⁶³, Alanna C Morrison⁶³, Scott Hazelhurst^{61,424}, Michèle Ramsay⁶¹, Kari E. North⁴²⁵,
 108 Martha Daviglus⁴²⁶, Peter Kraft^{59,427}, Nicholas G Martin⁴²⁸, John B Whitfield⁴²⁸, Shahid Abbas⁴²⁹,
 109 Danish Saleheen^{55,430,431}, Robin G Walters^{53,54,432}, Michael V Holmes^{53,54,433}, Corri Black⁴³⁴, Blair H
 110 Smith⁴³⁵, Aris Baras⁴¹⁹, Anne E Justice⁴³⁶, Julie E Buring^{50,437}, Paul M Ridker^{50,437}, Daniel I
 111 Chasman^{50,437}, Charles Kooperberg⁴⁹, Gen Tamiya⁴⁶, Masayuki Yamamoto⁴⁶, David A van Heel⁴⁸,
 112 Richard C Trembath⁴³⁸, Wei-Qi Wei⁴³⁹, Gail P Jarvik⁴⁴⁰, Bahram Namjou⁴⁴¹, M. Geoffrey
 113 Hayes^{442,443,444}, Marylyn D Ritchie⁴⁰, Pekka Jousilahti³⁹, Veikko Salomaa³⁹, Kristian Hveem^{34,445,446},
 114 Bjørn Olav Åsvold^{34,445,447}, Michiaki Kubo⁴⁴⁸, Yoichiro Kamatani^{25,449}, Yukinori Okada^{27,25,450,451},
 115 Yoshinori Murakami⁴⁵², Bong-Jo Kim⁴⁵³, Unnur Thorsteinsdottir^{21,454}, Kari Stefansson^{21,454}, Jifeng
 116 Zhang³, Y Eugene Chen³, Yuk-Lam Ho⁴⁵⁵, Julie A Lynch^{456,457}, Daniel Rader⁴⁵⁸, Philip S Tsao^{6,7,459},
 117 Kyong-Mi Chang^{460,458}, Kelly Cho^{455,461}, Christopher J O'Donnell^{455,461}, John M Gaziano^{455,461}, Peter
 118 Wilson^{17,462}, Karen L Mohlke¹⁷⁸, Timothy M Frayling⁷⁴, Joel N Hirschhorn^{463,10,464}, Sekar
 119 Kathiresan^{465,381,383}, Michael Boehnke¹³, Million Veterans Program, Global Lipids Genetics
 120 Consortium, Struan Grant^{1,374}, Pradeep Natarajan^{466,467,20,468}, Yan V Sun^{16,17}, Andrew P Morris⁴⁶⁹,
 121 Panos Deloukas^{4,470}, Gina Peloso⁴⁷¹, Themistocles L Assimes^{6,7,459}, Cristen J Willer^{3,472,148}, Xiang
 122 Zhu^{473,474,475,476}, Christopher D Brown¹

123

124 ¹Department of Genetics, Perelman School of Medicine, University of Pennsylvania,
 125 Philadelphia, PA 19104, USA, ²Department of Genetics, Stanford University School of
 126 Medicine, Stanford, CA, USA, ³Department of Internal Medicine, Division of Cardiology,
 127 University of Michigan, Ann Arbor, MI, 48109, USA, ⁴William Harvey Research Institute,
 128 Barts and the London School of Medicine and Dentistry, Queen Mary University of London,
 129 Charterhouse square, EC1M 6BQ, UK, ⁵Department of Biostatistics, Boston University
 130 School of Public Health, 801 Massachusetts Ave, Boston, MA 02118, USA, ⁶VA Palo Alto
 131 Health Care Systems, Palo Alto, California, USA, ⁷Department of Medicine, Division of
 132 Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305,
 133 USA, ⁸Department of Pathology and Laboratory Medicine, University of Pennsylvania,
 134 Philadelphia, PA, USA, ⁹Endocrinology, Boston Childrens Hospital, Boston 02115 MA, USA,
 135 ¹⁰Medical and Population Genetics, Broad Institute, 75 Ames street, Cambridge, MA
 136 02142, USA, ¹¹Department of Genetic Epidemiology, University of Regensburg, Regensburg,
 137 Germany, ¹²McDonnell Genome Institute and Department of Medicine, Washington
 138 University, St. Louis, MO, 63108, USA, ¹³Department of Biostatistics, Center for Statistical
 139 Genetics, University of Michigan, Ann Arbor, MI, USA, ¹⁴Department of Computational
 140 Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA, ¹⁵Clinical
 141 Pharmacology, William Harvey Research Institute, Barts and The London School of
 142 Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ UK,
 143 ¹⁶Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta,
 144 Georgia, USA, ¹⁷Atlanta VA Health Care System, Decatur, GA, USA, ¹⁸Malcolm Randall VA
 145 Medical Center, Gainesville, FL, USA, ¹⁹Division of Vascular Surgery and Endovascular
 146 Therapy, University of Florida College of Medicine, Gainesville, FL, USA, ²⁰Program in
 147 Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA,
 148 USA, ²¹deCODE genetics/Amgen, Inc. Sturlugata 8, Reykjavik, 102, Iceland, ²²School of

149 Engineering and Natural Sciences, University of Iceland, Sæmundargötu 2, Reykjavik, 102,
 150 Iceland, ²³Department of Clinical Biochemistry, Landspítali - National University Hospital of
 151 Iceland, Hringbraut, Reykjavik, 101, Iceland, ²⁴Division of Genome Science, Department of
 152 Precision Medicine, National Institute of Health, Chungcheongbuk-do, South Korea,
 153 ²⁵Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences,
 154 Yokohama, Japan, ²⁶Department of Ophthalmology, Graduate School of Medical Sciences,
 155 Kyushu University, Fukuoka, Japan, ²⁷Department of Statistical Genetics, Osaka University
 156 Graduate School of Medicine, Osaka, Japan, ²⁸Laboratory for Statistical Analysis, RIKEN
 157 Center for Integrative Medical Sciences, ²⁹Department of Allergy and Rheumatology,
 158 Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³⁰Laboratory for
 159 Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences,
 160 Yokohama, Japan, ³¹Program in Medical and Population Genetics, Broad Institute of MIT and
 161 Harvard, Cambridge, MA, USA., ³²Department of Biomedical Informatics, Harvard Medical
 162 School, Boston, MA, USA, ³³Analytic and Translational Genetics Unit, Massachusetts
 163 General Hospital, Boston, Massachusetts, USA, ³⁴K.G. Jebsen Center for Genetic
 164 Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of
 165 Science and Technology, Trondheim, Norway, ³⁵MRC Integrative Epidemiology Unit (IEU),
 166 Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8
 167 2BN, UK, ³⁶Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital,
 168 Trondheim, Norway, ³⁷Division of Medicine and Laboratory Sciences, University of
 169 Oslo, Norway, ³⁸Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of
 170 Helsinki, Tukholmankatu 8, 00014 Helsinki, Finland, ³⁹Department of Public Health and
 171 Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland, ⁴⁰Department of
 172 Genetics, Institute for Biomedical Informatics, University of Pennsylvania, Perelman School
 173 of Medicine, Philadelphia, PA 19104, USA, ⁴¹Center for Genetic Medicine, Northwestern

174 University, Feinberg School of Medicine, Chicago, IL 60611, USA, ⁴²Department of
 175 Medicine (Medical Genetics), University of Washington, WA, USA, ⁴³Division of Biomedical
 176 Informatics, Cincinnati Children's Hospital Medical Center, OH, USA, ⁴⁴Division of Clinical
 177 Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville,
 178 TN, USA, ⁴⁵Department of Cardiovascular Medicine and the Gonda Vascular Center, Mayo
 179 Clinic, Rochester, MN, USA, ⁴⁶Tohoku Medical Megabank Organization, Tohoku University,
 180 Sendai 980-8573, Japan, ⁴⁷Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK,
 181 ⁴⁸Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary
 182 University of London, London, UK, ⁴⁹Fred Hutchinson Cancer Research Center, Division of
 183 Public Health Sciences, Seattle WA 9810, USA, ⁵⁰Division of Preventive Medicine, Brigham
 184 and Women's Hospital, Boston, MA 02215, USA, ⁵¹Centre for Genomic and Experimental
 185 Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General
 186 Hospital, Edinburgh EH4 2XU, United Kingdom, ⁵²Usher Institute, The University of
 187 Edinburgh, Nine, Edinburgh Bioquarter, 9 Little France Road, Edinburgh, EH16 4UX, UK,
 188 ⁵³Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of
 189 Population Health, University of Oxford, Oxford OX3 7LF, UK, ⁵⁴Medical Research Council
 190 Population Health Research Unit, Nuffield Department of Population Health, University of
 191 Oxford, Oxford OX3 7LF, UK, ⁵⁵Center for Non-Communicable Diseases, Karachi, Sindh,
 192 Pakistan, ⁵⁶Department of Population Medicine, Qatar University College of Medicine, QU
 193 Health, Doha, Qatar, ⁵⁷Survey Research Center, Institute for Social Research, University of
 194 Michigan, Ann Arbor, MI, 48104, USA, ⁵⁸Department of Epidemiology, School of Public
 195 Health, University of Michigan, Ann Arbor, MI, 48109, USA, ⁵⁹Program in Genetic
 196 Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T.H. Chan
 197 School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA, ⁶⁰Department of
 198 Epidemiology, Gillings School of Global Public Health, University of North Carolina at

199 Chapel Hill, NC USA, ⁶¹Sydney Brenner Institute for Molecular Bioscience, Faculty of Health
 200 Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶²Wellcome Centre
 201 for Human Genetics, University of Oxford, UK, ⁶³Human Genetics Center, Department of
 202 Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The
 203 University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA,
 204 ⁶⁴Department of Epidemiology and Biostatistics, Imperial College London, London W2 1PG,
 205 UK, ⁶⁵Department of Cardiology, Ealing Hospital, London North West University Healthcare
 206 NHS Trust, Middlesex UB1 3HW, UK, ⁶⁶Imperial College Healthcare NHS Trust, London
 207 W12 0HS, UK, ⁶⁷Department of Medical Sciences, Molecular Epidemiology and Science for
 208 Life Laboratory, Uppsala University, Uppsala, Sweden, ⁶⁸MRC Epidemiology Unit,
 209 University of Cambridge School of Clinical Medicine, Cambridge, CB2 0QQ, UK,
 210 ⁶⁹Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care,
 211 University of Cambridge, Strangeways Research Laboratory, Wort's Causeway, Cambridge
 212 CB1 8RN, UK, ⁷⁰Center for Genomic Medicine, Kyoto University Graduate School of
 213 Medicine, Kyoto, Japan, ⁷¹Department of Internal Medicine, Erasmus MC, University Medical
 214 Center Rotterdam, the Netherlands, ⁷²Department of Biological Psychology, Vrije Universiteit
 215 Amsterdam, The Netherlands, ⁷³Amsterdam Public Health Research Institute, Amsterdam
 216 UMC, the Netherlands, ⁷⁴Genetics of Complex Traits, University of Exeter Medical School,
 217 University of Exeter, Exeter, EX2 5DW, UK, ⁷⁵Department of Clinical Acupuncture and
 218 Moxibustion, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China,
 219 ⁷⁶Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research
 220 Center for Environmental Health, Neuherberg, Germany, ⁷⁷Institute of Epidemiology,
 221 Helmholtz Zentrum München, German Research Center for Environmental Health,
 222 Neuherberg, Germany, ⁷⁸Bristol Dental School, University of Bristol, Lower Maudlin Street,
 223 Bristol BS1 2LY, United Kingdom, ⁷⁹Population Health Sciences, Bristol Medical School,

224 University of Bristol, Oakfield Grove, Bristol, BS8 2BN, United Kingdom, ⁸⁰Saw Swee Hock
 225 School of Public Health, National University of Singapore and National University Health
 226 System, 117549, Singapore, ⁸¹Center for Clinical Research and Prevention, Bispebjerg and
 227 Frederiksberg Hospital, Copenhagen, Denmark, ⁸²Department of Clinical Medicine, Faculty of
 228 Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁸³The
 229 Institute for Translational Genomics and Population Sciences, Department of Pediatrics,
 230 Lundquist Institute for Biomedical Innovations (Formerly LABioMed) at Harbor-UCLA
 231 Medical Center, Torrance, CA 90502, USA, ⁸⁴Center for Public Health Genomics, University
 232 of Virginia, Charlottesville, VA 22903 USA, ⁸⁵Department of Medical Research, Taichung
 233 Veterans General Hospital, Taichung, Taiwan; No. 1650, Sec. 4, Taiwan Boulevard,
 234 Taichung City 40705, Taiwan, ⁸⁶Institute of Population Health Sciences, National Health
 235 Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC,
 236 ⁸⁷William Harvey Research Institute, Barts and The London School of Medicine and
 237 Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse
 238 Square, London, EC1M 6BQ, UK, ⁸⁸NIHR Barts Cardiovascular Biomedical Research Centre,
 239 Barts and The London School of Medicine and Dentistry, Queen Mary University of London,
 240 London, EC1M 6BQ, UK, ⁸⁹Novo Nordisk Foundation Center for Basic Metabolic Research,
 241 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark,
 242 ⁹⁰Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe
 243 Hospital, University of Oxford, Oxford. UK. OX3 9DU, ⁹¹Wellcome Centre for Human
 244 Genetics, University of Oxford, Oxford. UK. OX3 7BN, ⁹²Unit of Genomics of Complex
 245 Diseases. Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain,
 246 ⁹³Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Center for
 247 Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden, ⁹⁴Department of
 248 Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center,

249 Leiden, the Netherlands, ⁹⁵Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle
 250 Ricerche, Italy, ⁹⁶Dipartimento di Scienze Biomediche, Università degli Studi di Sassari,
 251 Sardinia, Italy, ⁹⁷University Center for Primary Care and Public Health, University of
 252 Lausanne, Rte de Berne 113, Lausanne, 1010, Switzerland, ⁹⁸Swiss Institute of
 253 Bioinformatics, Lausanne, 1015, Switzerland, ⁹⁹Department of Medicine, Internal Medicine,
 254 Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, Lausanne,
 255 1011, Switzerland, ¹⁰⁰Department of Epidemiology and Biostatistics, MRC-PHE Centre for
 256 Environment and Health, School of Public Health, Imperial College London, London, UK,
 257 ¹⁰¹Dept of Cardiology, Leiden University Medical Center, Leiden, the Netherlands, ¹⁰²Dept of
 258 Internal Medicine, Section of Gerontology and Geriatrics, Leiden university Medical Center,
 259 Leiden, the Netherlands, ¹⁰³BHF Glasgow Cardiovascular Research Centre, Faculty of
 260 Medicine, Glasgow, United Kingdom, ¹⁰⁴Institute for Cardiogenetics, University of Lübeck,
 261 DZHK (German Research Centre for Cardiovascular Research), partner site
 262 Hamburg/Lübeck/Kiel, University Heart Center Lübeck, Lübeck and Charité – University
 263 Medicine Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu
 264 Berlin, and Berlin Institute of Health, Institute for Dental and Craniofacial Sciences,
 265 Department of Periodontology and Synoptic Dentistry, Berlin, Germany, ¹⁰⁵Deutsches
 266 Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Technische Universität
 267 München, Munich, Germany., ¹⁰⁶Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
 268 e.V., partner site Munich Heart Alliance, Munich, Germany., ¹⁰⁷Key Laboratory of
 269 Cardiovascular Epidemiology & Department of Epidemiology, State Key Laboratory of
 270 Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases,
 271 Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037,
 272 China, ¹⁰⁸Lund University Diabetes Centre, Malmö, Sweden, ¹⁰⁹Institute of Genetic
 273 Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck,

274 Innsbruck, Austria and German Chronic Kidney Disease Study, Austria, ¹¹⁰Institute for
 275 Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16-
 276 18, 04107 Leipzig, Germany, ¹¹¹LIFE Research Centre for Civilization Diseases, University of
 277 Leipzig, Philipp-Rosenthal-Straße 27, 04103 Leipzig, Germany, ¹¹²Radboud university
 278 medical center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands,
 279 ¹¹³Quantinuum Research LLC, Wayne, PA, 19087 USA, ¹¹⁴Division of Statistical Genomics,
 280 Department of Genetics; Washington University School of Medicine; St. Louis, MO, USA,
 281 ¹¹⁵Department of Epidemiology; University of Pittsburgh; Pittsburgh, PA, USA, ¹¹⁶Institute for
 282 Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Via Galvani
 283 31, 39100, Bolzano, Italy, ¹¹⁷Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle,
 284 Denmark, ¹¹⁸Cardiovascular Health Research Unit, Department of Medicine, University of
 285 Washington, Seattle, 98101, USA, ¹¹⁹Department of Anthropology, University of Toronto at
 286 Mississauga, Mississauga, ON L5L 1C6, Canada, ¹²⁰Department of Computer Science,
 287 University of Toronto, Toronto, ON M5S 2E4, Canada, ¹²¹The Charles Bronfman Institute for
 288 Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA,
 289 ¹²²Department of Twin Research and Genetic Epidemiology, King's College London, London
 290 SE1 7EH, UK, ¹²³NIHR Biomedical Research Centre at Guy's and St Thomas' Foundation
 291 Trust, London SE1 9RT, UK, ¹²⁴Department of Cardiology, University of Groningen,
 292 University Medical Center Groningen, 9700RB Groningen, the Netherlands, ¹²⁵Institute of
 293 Cardiovascular Sciences, University College London, Gower Street, WC1E 6BT London,
 294 UK, ¹²⁶Department of Epidemiology and Public Health, University College London, 1-19
 295 Torrington Place, WC1E 6BT London, United Kingdom, ¹²⁷Department of Surgery, University
 296 of Pennsylvania, Philadelphia, PA, ¹²⁸Amsterdam UMC, Department of Epidemiology and
 297 Data Science, Amsterdam Public Health Research Institute, Amsterdam, 1081HV, the
 298 Netherlands, ¹²⁹Leiden University Medical Center, Department of Cell and Chemical Biology,

299 Leiden, 2333ZA, the Netherlands, ¹³⁰Montreal Heart Institute, Université de Montréal, 5000
 300 Belanger street, Montreal, PQ, Canada H1T1C8, ¹³¹Icelandic Heart Association, 201
 301 Kopavogur, Iceland, ¹³²Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg
 302 University, 68167 Mannheim, Germany, ¹³³SYNLAB MVZ Humangenetik Mannheim GmbH,
 303 68163 Mannheim, Germany, ¹³⁴Shanghai Institute of Nutrition and Health, University of
 304 Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China, ¹³⁵Biomedical
 305 Technology Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co.,
 306 Ltd., Tokushima, Japan, ¹³⁶School of Life Sciences, Westlake University, Hangzhou, Zhejiang
 307 310024, China, ¹³⁷Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou,
 308 Zhejiang 310024, China, ¹³⁸Institute for Molecular Bioscience, The University of Queensland,
 309 Brisbane, Queensland 4072, Australia, ¹³⁹Nuffield Department of Population Health,
 310 University of Oxford, Oxford, United Kingdom, ¹⁴⁰Department of Epidemiology, Erasmus
 311 MC, University Medical Center Rotterdam, the Netherlands, ¹⁴¹Department of Epidemiology,
 312 Erasmus MC, University Medical Center, Rotterdam, the Netherlands, ¹⁴²Section of Statistical
 313 Multi-omics, Department of Clinical and Experimental research, University of Surrey,
 314 Guildford, Surrey, UK, ¹⁴³Laboratory of Neurogenetics, National Institute on Aging, NIH,
 315 Bethesda MD, USA, ¹⁴⁴Data Tecnica International, Glen Echo MD, USA, ¹⁴⁵MRC Human
 316 Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General
 317 Hospital, Crewe Road, Edinburgh, EH4 2XU, Scotland, ¹⁴⁶Institute for Medical Informatics,
 318 Biometrie and Epidemiology, University of Duisburg-Essen, Essen, Germany, ¹⁴⁷Centre for
 319 Public Health, Queen's University of Belfast, Northern Ireland, ¹⁴⁸Genomic Oncology Area,
 320 GENYO, Centre for Genomics and Oncological Research: Pfizer-University of Granada-
 321 Andalusian Regional Government, Granada, Spain, ¹⁴⁹Hematology Department, Hospital
 322 Universitario Virgen de las Nieves, Granada, Spain, ¹⁵⁰Instituto de Investigación Biosanitaria
 323 de Granada (ibs.GRANADA), Granada, Spain, ¹⁵¹Department of Epidemiology and

324 Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of
 325 Science and Technology, Wuhan, China, ¹⁵²Genome Institute of Singapore, Agency for
 326 Science, Technology and Research, Singapore, ¹⁵³Public Health Informatics Unit, Department
 327 of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya,
 328 461-8673, Japan, ¹⁵⁴University of Alabama at Birmingham, Epidemiology, School of Public
 329 Health, AL, USA, ¹⁵⁵Tampere Centre for Skills Training and Simulation, Faculty of Medicine
 330 and Health Technology, Tampere University, Tampere, Finland, ¹⁵⁶Brown Foundation
 331 Institute of Molecular Medicine, McGovern Medical School, University of Texas Health
 332 Science Center at Houston, Houston TX 77030, USA, ¹⁵⁷CONACYT, Instituto Nacional de
 333 Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico, ¹⁵⁸Departamento
 334 de Genómica Computacional, Instituto Nacional de Medicina Genómica, Ciudad de Mexico,
 335 Mexico, ¹⁵⁹Center for diabetes research, University of Bergen, Bergen, Norway, ¹⁶⁰Lund
 336 University Diabetes Center, Lunds University, Malmö, Sweden, ¹⁶¹Genomic Research on
 337 Complex diseases (GRC Group), CSIR-Centre for Cellular and Molecular Biology,
 338 Hyderabad, Telangana, India, ¹⁶²Academy of Scientific and Innovative Research (AcSIR),
 339 New Delhi, India, ¹⁶³Hunter Medical Research Institute, Newcastle, Australia, ¹⁶⁴Medical
 340 Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of
 341 Medicine, Seoul, 03181, Korea, ¹⁶⁵Department of Clinical Research Design & Evaluation,
 342 SAIHST, Sungkyunkwan University, Seoul, 06355, Korea, ¹⁶⁶Center for Cohort Studies, Total
 343 Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of
 344 Medicine, Seoul, 04514, Korea, ¹⁶⁷Department of Occupational and Environmental Medicine,
 345 Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 03181,
 346 Korea, ¹⁶⁸Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot
 347 Place, Edinburgh, EH8 9AG, Scotland, ¹⁶⁹Thurston Arthritis Research Center, University of
 348 North Carolina, Chapel Hill, North Carolina, USA, ¹⁷⁰Health Services and Systems Research,

349 Duke-NUS Medical School, 169857, Singapore, ¹⁷¹Division of Biomedical Informatics and
 350 Personalized Medicine, Department of Medicine, Anschutz Medical Campus, University of
 351 Colorado, Denver, Aurora, CO 80045, USA, ¹⁷²Genomics and Molecular Medicine Unit,
 352 CSIR-Institute of Genomics and Integrative Biology, New Delhi - 110020, India, ¹⁷³Academy
 353 of Scientific and Innovative Research, CSIR-Human Resource Development Centre,
 354 Ghaziabad, Uttar Pradesh, India, ¹⁷⁴Departments of Ophthalmology and Human Genetics,
 355 Radboud University Nijmegen Medical Center, Philips van Leydenlaan 15, Nijmegen, 6525
 356 EX, the Netherlands, ¹⁷⁵Vanderbilt Epidemiology Center, Division of Epidemiology,
 357 Vanderbilt University Medical Center, USA, ¹⁷⁶Department of Pediatrics, University of
 358 California San Francisco, Oakland, CA 94609 USA, ¹⁷⁷National Center for Global Health and
 359 Medicine, Tokyo, 1628655, Japan, ¹⁷⁸Department of Genetics, University of North Carolina,
 360 Chapel Hill, NC 27599 USA, ¹⁷⁹Department of Biostatistics and Epidemiology, University of
 361 Massachusetts-Amherst, Amherst, MA 01003 USA, ¹⁸⁰Department of Cardiovascular
 362 Sciences, University of Leicester, Leicester, UK, ¹⁸¹NIHR Leicester Biomedical Research
 363 Centre, Glenfield Hospital, Leicester, UK, ¹⁸²Beijing Institute of Ophthalmology, Beijing Key
 364 Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Eye Center, Beijing
 365 Tongren Hospital, Capital Medical University, 17 Hougou Lane, Chong Wen Men, Beijing,
 366 100005 , China, ¹⁸³Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical
 367 University, 1 Dong Jiao Min Xiang, Dong Cheng District, Beijing, 100730, China, ¹⁸⁴Institute
 368 of Genetics and Biophysics "Adriano Buzzati-Traverso" - CNR, Naples, Italy, ¹⁸⁵IRCCS
 369 Neuromed, Pozzilli, Isernia, Italy, ¹⁸⁶Division of Biostatistics, Washington University, St.
 370 Louis, MO 63110, USA, ¹⁸⁷Rush Alzheimer's Disease Center, Rush University Medical
 371 Center, IL, USA, ¹⁸⁸Department of Neurological Sciences, Rush University Medical Center,
 372 IL, USA, ¹⁸⁹Dept of Nephrology, University Hospital Regensburg, Regensburg, Germany,
 373 ¹⁹⁰Institute for Maternal and Child Health—IRCCS, Burlo Garofolo, 34127 Trieste, Italy,

¹⁹¹Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany, ¹⁹²German Center for Diabetes Research (DZD), München-Neuherberg, Germany, ¹⁹³Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Kuwait, ¹⁹⁴Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University of Athens, Athens, Greece, ¹⁹⁵Department of Population Science and Experimental Medicine, University College London, London, UK, ¹⁹⁶Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria, ¹⁹⁷Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria, ¹⁹⁸Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA, ¹⁹⁹Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy, ²⁰⁰Institute of Genetic and Biomedical Research, National Research Council of Italy, UOS of Sassari, Sassari, Italy, ²⁰¹Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, 9700 RB, the Netherlands, ²⁰²Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland, ²⁰³Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland, ²⁰⁴Sleep Medicine and Circadian Disorders, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA, ²⁰⁵Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA, ²⁰⁶Central Diagnostics Laboratory, Division Laboratories, Pharmacy, and Biomedical genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, ²⁰⁷Laboratory of Epidemiology and Population Science National Institute on Aging Intramural Research Program, NIH, USA, ²⁰⁸Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA, ²⁰⁹Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University of Greifswald and University Medicine Greifswald, Greifswald, Germany, ²¹⁰Center for Research on Genomics and Global Health, National

399 Human Genome Research Institute, National Institutes of Health, 12 South Drive, Room
 400 4047, Bethesda, MD, 20892, USA, ²¹¹Oneomics. co. ltd. 2F, Soonchunhyang Mirai Medical
 401 Center 173, Buheuyng-ro, Bucheon-si Gyeonggi-do, 14585, Korea, ²¹²Department of Clinical
 402 Biochemistry and Immunology, Hospital of Southern Jutland, Kresten Philipsens Vej 15,
 403 6200 Aabenraa, Denmark, ²¹³Department of Clinical Biochemistry, Lillebaelt Hospital,
 404 Kolding, Denmark, ²¹⁴Department of Biomedical Science, Hallym University, Chuncheon,
 405 Gangwon-do 24252, Korea, ²¹⁵Centre for Bone and Arthritis Research, Department of Internal
 406 Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of
 407 Gothenburg, Gothenburg, Sweden, ²¹⁶Bioinformatics Core Facility, Sahlgrenska Academy,
 408 University of Gothenburg, Gothenburg, Sweden, ²¹⁷Institute of Medical Informatics and
 409 Statistics, Kiel University, Kiel, Germany, ²¹⁸Institute of Translational Genomics, Helmholtz
 410 Zentrum München – German Research Center for Environmental Health, Neuherberg,
 411 Germany, ²¹⁹Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK,
 412 ²²⁰Oxford Centre for Diabetes Endocrinology and Metabolism, Oxford, UK, ²²¹School of
 413 Medicine and Public Health, Faculty of Medicine and Health, University of Newcastle,
 414 Newcastle, New South Wales, 2308, Australia, ²²²Center for Geriatrics and Gerontology,
 415 Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung
 416 Veterans General Hospital, Taichung, Taiwan, ²²³School of Medicine, National Yang-Ming
 417 University, Taipei, Taiwan, ²²⁴School of Medicine, National Defense Medical Center, Taipei,
 418 Taiwan, ²²⁵Division of Endocrinology and Metabolism, Department of Internal Medicine,
 419 Taichung Veterans General Hospital, Taichung, Taiwan, ²²⁶Department of Medicine, School
 420 of Medicine, National Yang-Ming University, Taipei, Taiwan, ²²⁷Department of Kinesiology,
 421 Université Laval, Québec, Canada, ²²⁸Department of Clinical Chemistry, Fimlab Laboratories,
 422 Tampere 33520, Finland, ²²⁹Department of Clinical Chemistry, Finnish Cardiovascular
 423 Research Center - Tampere, Faculty of Medicine and Health Technology, Tampere

424 University, Tampere 33014, Finland, ²³⁰Department of Cardiology, Heart Center, Tampere
 425 University Hospital, Tampere 33521, Finland, ²³¹Department of Cardiology, Finnish
 426 Cardiovascular Research Center - Tampere, Faculty of Medicine and Health Technology,
 427 Tampere University, Tampere 33014, Finland, ²³²University of Queensland Diamantina
 428 Institute, Translational Research Institute, Kent St, Woolloongabba, Brisbane, QLD, 4102,
 429 Australia, ²³³Department of Medicine, Bornholms Hospital, Rønne, Denmark, ²³⁴School of
 430 Public Health, University of Alabama at Birmingham, AL, USA, ²³⁵Cardiology, Division
 431 Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the
 432 Netherlands, ²³⁶Department of Population and Quantitative Health Sciences, Case Western
 433 Reserve University, Cleveland, OH, 44106, USA, ²³⁷Department of Genetics, Stanford
 434 University School of Medicine Stanford, CA 94305, USA, ²³⁸Department of Epidemiology -
 435 Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands, ²³⁹Ohio
 436 State University, Division of Endocrinology, Columbus OH 43210, USA, ²⁴⁰University of
 437 Washington, Department of Epidemiology, Seattle WA 98195, USA, ²⁴¹George Washington
 438 University, School of Medicine and Health Sciences, Washington DC 20037, USA,
 439 ²⁴²Department of Epidemiology, School of Public Health, Peking University Health Science
 440 Center, Beijing, China, ²⁴³Institute for Laboratory Medicine, University Hospital Leipzig,
 441 Paul-List-Strasse 13/15, 04103 Leipzig, Germany, ²⁴⁴Laboratory of Epidemiology and
 442 Population Sciences, National Institute on Aging, NIH, Baltimore, MD, 20892-9205, USA,
 443 ²⁴⁵Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences,
 444 Chinese Academy of Sciences, Shanghai, China, ²⁴⁶Centre for Population Health Research,
 445 University of Turku and Turku University Hospital, Finland, ²⁴⁷Research Centre of Applied
 446 and Preventive Cardiovascular Medicine, University of Turku, Finland, ²⁴⁸Department of
 447 Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland,
 448 ²⁴⁹Department of Environmental and Preventive Medicine, Jichi Medical University School of

449 Medicine, Shimotsuke, 329-0498, Japan, ²⁵⁰Centre for Population Health Sciences, Usher
 450 Institute, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, Scotland,
 451 ²⁵¹Department of Functional Pathology, Shimane University School of Medicine, Izumo,
 452 6938501, Japan, ²⁵²Department of Pediatrics and Adolescent Medicine, Turku University
 453 Hospital and University of Turku, Turku, Finland, ²⁵³Department of Physiology, University of
 454 Turku, Turku, Finland, ²⁵⁴Faculty of Medicine, University of Split, Šoltanska 2, HR-21000,
 455 Split, Croatia, ²⁵⁵Medical Department III – Endocrinology, Nephrology, Rheumatology,
 456 University of Leipzig Medical Center, Liebigstr. 21, 04103 Leipzig, Germany, ²⁵⁶Department
 457 of Nutrition-Dietetics, Harokopio University, Eleftheriou Venizelou, Athens, 17676, Greece,
 458 ²⁵⁷Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine,
 459 Suita, 5650871, Japan, ²⁵⁸Department of Geriatric and General Medicine, Osaka University
 460 Graduate School of Medicine, Suita, 5650871, Japan, ²⁵⁹Department of Vascular Surgery,
 461 Division of Surgical Specialties, University Medical Center Utrecht, Utrecht University,
 462 Utrecht, the Netherlands, ²⁶⁰Corneal Dystrophy Research Institute, Department of
 463 Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Korea, ²⁶¹Dept of
 464 Radiology and Nuclear Medicine, Erasmus MC - University Medical Center Rotterdam,
 465 Rotterdam, the Netherlands, ²⁶²Julius Centre for Health Sciences and Primary Care, University
 466 Medical Centre Utrecht, 3584CG, the Netherlands, ²⁶³Second Department of Cardiology,
 467 Medical School, National and Kapodistrian University of Athens, Attikon University
 468 Hospital, Athens, Greece, ²⁶⁴Center for Vision Research, Department of Ophthalmology and
 469 The Westmead Institute, University of Sydney, Hawkesbury Rd, Sydney, New South Wales,
 470 2145, Australia, ²⁶⁵Menzies Institute for Medical Research, School of Medicine, University of
 471 Tasmania, Liverpool St, Hobart, Tasmania, 7000, Australia, ²⁶⁶Centre for Eye Research
 472 Australia, University of Melbourne, Melbourne, Victoria, 3002, Australia, ²⁶⁷Department of
 473 Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland, ²⁶⁸Department of

474 Clinical Physiology, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine
 475 and Health Technology, Tampere University, Tampere 33014, Finland, ²⁶⁹Centre Nutrition,
 476 santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Québec,
 477 Canada, ²⁷⁰Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA, ²⁷¹Medical
 478 Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical
 479 Center, Liebigstr. 18, 04103 Leipzig, Germany, ²⁷²Discipline of Internal Medicine, Medical
 480 School, The University of Western Australia, Perth, WA, Australia, ²⁷³Institute of
 481 Epidemiology, Kiel University, Kiel, Germany, ²⁷⁴Institute of Clinical Molecular Biology,
 482 Kiel University, Kiel, Germany, ²⁷⁵Sahlgrenska University Hospital, Department of Drug
 483 Treatment, Gothenburg, Sweden, ²⁷⁶Geriatric Medicine, Institute of Medicine, Sahlgrenska
 484 Academy, University of Gothenburg, Gothenburg, Sweden, ²⁷⁷Department of Internal
 485 Medicine, EwhaWomans University School of Medicine, Seoul, Korea, ²⁷⁸Division of Cancer
 486 Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh,
 487 Pittsburgh, PA 15232, USA, ²⁷⁹Department of Epidemiology, Graduate School of Public
 488 Health, University of Pittsburgh, Pittsburgh, PA 15232, USA, ²⁸⁰Healthy Longevity
 489 Translational Research Programme, Yong Loo Lin School of Medicine, National University
 490 of Singapore, Singapore 117545, Singapore, ²⁸¹Singapore Institute for Clinical Sciences,
 491 Agency for Science Technology and Research (A*STAR), Singapore 117609, Singapore,
 492 ²⁸²Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine,
 493 Seoul 02447, Korea, ²⁸³Institute for Community Medicine, University Medicine Greifswald,
 494 Germany, ²⁸⁴Laboratory of Epidemiology and Population Science National Institute on Aging
 495 Intramural Research Program, NIH 251 Bayview Blvd, NIH Biomedical Research Center,
 496 Baltimore, MD 21224, USA, ²⁸⁵Algebra University College, Ilica 242, Zagreb, Croatia,
 497 ²⁸⁶Paavo Nurmi Centre, Sports and Exercise Medicine Unit, Department of Physical Activity
 498 and Health, University of Turku, Turku, Finland, ²⁸⁷Interdisciplinary Center Psychopathology

499 and Emotion Regulation (ICPE), University of Groningen, University Medical Center
 500 Groningen, Groningen, 9700 RB, the Netherlands, ²⁸⁸Institute of Molecular Genetics, National
 501 Research Council of Italy, Pavia, Italy, ²⁸⁹Gottfried Schatz Research Center for Cell Signaling,
 502 Metabolism and Aging, Medical University of Graz, Graz, Austria, ²⁹⁰Local Health Unit
 503 Toscana Centro, Firenze, Italy, ²⁹¹Institute of Nutritional Science, University of Potsdam,
 504 Nuthetal, Germany, ²⁹²Department of Medicine, Surgery and Health Sciences, University of
 505 Trieste, Strada di Fiume 447, 34149, Trieste, Italy, ²⁹³Dept of Nephrology, Diabetology,
 506 Rheumatology; Traunstein Hospital, Traunstein, Germany, ²⁹⁴KfH Kidney Center Traunstein,
 507 Traunstein, Germany, ²⁹⁵Center for Translational and Systems Neuroimmunology, Department
 508 of Neurology, Columbia University Medical Center, New York, NY, USA, ²⁹⁶Program in
 509 Medical and Population Genetics, Broad Institute, Cambridge, MA, USA, ²⁹⁷Medical School,
 510 National and Kapodistrian University Athens, 75 M. Assias Street, 115 27 Athens, Greece,
 511 ²⁹⁸Dromokaiteio Psychiatric Hospital, 124 61 Athens, Greece, ²⁹⁹Clinical Pharmacology,
 512 William Harvey Research Institute, Queen Mary University of London, London, EC1M
 513 6BQ, UK, ³⁰⁰Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg
 514 University, Kutzerufer 1, Mannheim, 68167, Germany, ³⁰¹Institute of Molecular and Clinical
 515 Ophthalmology Basel, Switzerland, ³⁰²Privatpraxis Prof Jonas und Dr Panda-Jonas,
 516 Heidelberg, Germany, ³⁰³Department of Human Genetics, David Geffen School of Medicine at
 517 UCLA, University of California, Los Angeles, CA, USA, ³⁰⁴Unidad de Biología Molecular y
 518 Medicina Genómica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
 519 Mexico 14080, Mexico, ³⁰⁵Instituto de Investigaciones Biomédicas, UNAM, Mexico,
 520 ³⁰⁶Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y
 521 Nutrición Salvador Zubirán, Mexico 14080, Mexico, ³⁰⁷Department of Nutrition, Gillings
 522 School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina,
 523 27599 USA, ³⁰⁸Carolina Population Center, University of North Carolina, Chapel Hill, North

524 Carolina, 27516 USA, ³⁰⁹USC–Office of Population Studies Foundation, University of San
 525 Carlos, Cebu City, 6000, Philippines, ³¹⁰Department of Anthropology, Sociology, and History,
 526 University of San Carlos, Cebu City, 6000 Philippines, ³¹¹Department of Medicine, Faculty of
 527 Medicine, University of Kelaniya, Ragama, 11010, Sri Lanka, ³¹²Department of Public Health,
 528 Faculty of Medicine, University of Kelaniya, Ragama, 11010, Sri Lanka, ³¹³Children's
 529 Hospital Oakland Research Institute, Oakland, CA 94609 USA, ³¹⁴Institute of Biomedical
 530 Sciences, Academia Sinica, Taiwan, ³¹⁵Systems Genomics Laboratory, School of
 531 Biotechnology, Jawaharlal Nehru University, New Delhi - 110067, India, ³¹⁶Department of
 532 Medicine, University of Mississippi Medical Center, Jackson, MS, 39216, USA,
 533 ³¹⁷Department of Physiology and Biophysics, University of Mississippi Medical Center,
 534 Jackson, MS, 39216, USA, ³¹⁸Department of Medical Sciences, Uppsala University, Sweden,
 535 ³¹⁹Department of Paediatrics, Yong Loo Lin School of Medicine, National University of
 536 Singapore; and Khoo Teck Puat - National University Children's Medical Institute, National
 537 University Health System, Singapore, ³²⁰Department of Medicine, University of North
 538 Carolina, Chapel Hill, NC, USA, ³²¹Department of Epidemiology, Gillings School of Global
 539 Public Health, University of North Carolina, Chapel Hill, North Carolina, USA, ³²²Injury
 540 Prevention Research Center, University of North Carolina, Chapel Hill, North Carolina,
 541 USA, ³²³Division of Physical Therapy, University of North Carolina, Chapel Hill, North
 542 Carolina, USA, ³²⁴Department of Psychiatry, Amsterdam UMC, Vrije Universiteit
 543 Amsterdam, the Netherlands, ³²⁵Amsterdam Public Health research institute, VU medical
 544 center Amsterdam, the Netherlands, ³²⁶Department of Biochemistry, College of Medicine,
 545 Ewha Womans University, Seoul 07804, Korea, ³²⁷Faculty of Health and Medicine, University
 546 of Newcastle, Australia, ³²⁸Washington University School of Medicine, Division of
 547 Biostatistics, MO, USA, ³²⁹University of Kentucky, College of Public Health, KY, USA,
 548 ³³⁰Institute of Cellular Medicine (Diabetes), The Medical School, Newcastle University,

549 Framlington Place, Newcastle upon Tyne, NE2 4HH, UK, ³³¹University of Helsinki and
 550 Department of Medicine, Helsinki University Hospital, P.O.Box 340, Haartmaninkatu 4,
 551 Helsinki, FI-00029, Finland, ³³²Minerva Foundation Institute for Medical Research,
 552 Biomedicum 2U, Tukholmankatu 8, Helsinki, FI-00290, Finland, ³³³JSS Academy of Higher
 553 Education and Research, Mysuru, India, ³³⁴Programs in Metabolism and Medical and
 554 Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA, ³³⁵Diabetes
 555 Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA,
 556 USA10, ³³⁶Harvard Medical School, Boston, Massachusetts, USA, ³³⁷Unidad de Biología
 557 Molecular y Medicina Genómica, Instituto de Investigaciones Bimédicas UNAM/ Instituto
 558 Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
 559 ³³⁸Dirección de Nutrición and Unidad de Estudios de Enfermedades Metabólicas, Instituto
 560 Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
 561 ³³⁹Instituto Nacional de Salud Publica y Centro de Estudios en Diabetes, Mexico, ³⁴⁰Instituto
 562 Nacional de Medicina Genómica, Mexico, ³⁴¹Human Genetics Center, School of Public
 563 Health, University of Texas Health Science Center at Houston, Houston TX 77030, USA,
 564 ³⁴²Yong Loo Lin School of Medicine, National University of Singapore and National
 565 University Health System, 119228, Singapore, ³⁴³MRC Unit for Lifelong Health and Ageing at
 566 UCL, 1-19 Torrington Place, London, WC1E 7HB, United Kingdom, ³⁴⁴Kurume University
 567 School of Medicine, Kurume, 830-0011, Japan, ³⁴⁵Genetics, Merck Sharp & Dohme Corp.,
 568 Kenilworth, NJ, 07033, USA, ³⁴⁶Oxford Centre for Diabetes, Endocrinology & Metabolism,
 569 University of Oxford, UK, ³⁴⁷Population Health and Genomics, University of Dundee,
 570 Ninwells Hospital and Medical School, Dundee, DD1 9SY, UK, ³⁴⁸Intramural Research
 571 Program, National Institute on Aging, 3001 S. Hanover St., Baltimore, MD 21225, ³⁴⁹Beijing
 572 Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital
 573 Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, 100730

574 Beijing, China, ³⁵⁰The Eye Hospital, School of Ophthalmology & Optometry, Wenzhou
 575 Medical University, Wenzhou, Zhejiang 325027, China, ³⁵¹Synlab Academy, SYNLAB
 576 Holding Deutschland GmbH, Mannheim and Augsburg, Germany, ³⁵²Clinical Institute of
 577 Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria,
 578 ³⁵³Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland, ³⁵⁴Leiden University
 579 Medical Center, Department of Cell and Chemical Biology, Leiden, 2333ZA, The
 580 Netherlands, ³⁵⁵Leiden University Medical Center, Department of Biomedical Data Sciences,
 581 Section Molecular Epidemiology, Leiden, 2333ZA, The Netherlands, ³⁵⁶Amsterdam UMC,
 582 Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute,
 583 Amsterdam, 1081HV, the Netherlands., ³⁵⁷Amsterdam UMC, Department of General Practice
 584 and Elderly Care, Amsterdam Public Health Research Institute, Amsterdam, 1081HV, The
 585 Netherlands, ³⁵⁸Department of Genetics, University of Pennsylvania, Philadelphia, PA, 19104,
 586 USA, ³⁵⁹Department of Surgery, University of Pennsylvania, Philadelphia, PA, 19104, USA,
 587 ³⁶⁰Corporal Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania, PA, 19104,
 588 USA, ³⁶¹Institute of Social and Economic Research, University of Essex, Wivenhoe Park, CO4
 589 3SQ, United Kingdom, ³⁶²Department of Cardiology, University of Groningen, University
 590 Medical Center Groningen, 9700RB Groningen, The Netherlands, ³⁶³Department of
 591 Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New
 592 York, NY, USA, ³⁶⁴Unidad de Investigacion Medica en Bioquimica, Hospital de
 593 Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social,
 594 Mexico City, Mexico., ³⁶⁵Department of Epidemiology, University of Washington, Seattle,
 595 WA, USA, ³⁶⁶Department of Health Services, University of Washington, Seattle, WA, USA,
 596 ³⁶⁷Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark,
 597 ³⁶⁸16Center for Research on Genomics and Global Health, National Human Genome Research
 598 Institute, National Institutes of Health, 12 South Drive, Room 4047, Bethesda, MD, 20892,

599 USA,,³⁶⁹Danish Aging Research Center, University of Southern Denmark; Odense C,
 600 Denmark, ³⁷⁰Public Health, Faculty of Medicine, University of Helsinki, Finland, ³⁷¹Broad
 601 Institute of MIT and Harvard, Cambridge, MA, ³⁷²Center for Applied Genomics, Children's
 602 Hospital of Philadelphia, Philadelphia, PA, 19104 USA, ³⁷³Department of Pediatrics, The
 603 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104 USA,
 604 ³⁷⁴Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104
 605 USA, ³⁷⁵Department of Genetics, University of Pennsylvania, Philadelphia, PA, 19104 USA,
 606 ³⁷⁶Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The
 607 Netherlands, ³⁷⁷School of Medicine, Southern University of Science and Technology,
 608 Shenzhen, China, ³⁷⁸Institute for Cardiogenetics, University of Lübeck, DZHK (German
 609 Research Centre for Cardiovascular Research), partner site Hamburg/Lübeck/Kiel, and
 610 University Heart Center Lübeck, Lübeck, Germany, ³⁷⁹Netherlands Heart Institute, Utrecht,
 611 the Netherlands, ³⁸⁰Division of Cardiology, Department of Medicine, Massachusetts General
 612 Hospital, Boston, Massachusetts, USA, ³⁸¹Program of Medical and Population Genetics, Broad
 613 Institute, Cambridge, Massachusetts, USA, ³⁸²Center for Genomic Medicine, Massachusetts
 614 General Hospital, Boston, Massachusetts, USA, ³⁸³Department of Medicine, Harvard Medical
 615 School, Boston, Massachusetts, USA, ³⁸⁴Northern Finland Birth Cohorts, Infrastructure for
 616 population studies, Faculty of Medicine, University of Oulu, Oulu, Finland, ³⁸⁵Center for Life
 617 Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland, ³⁸⁶Biocenter
 618 of Oulu, University of Oulu, Oulu, Finland, ³⁸⁷Institute for Genetic and Biomedical Research,
 619 Italian National Council of Research (IRGB CNR), Cagliari, Italy, ³⁸⁸University of Sassari,
 620 Sassari, Italy, ³⁸⁹Department of Clinical Epidemiology, Leiden University Medical Center,
 621 Leiden, the Netherlands, ³⁹⁰Department of Public Health and Primary Care, Leiden University
 622 Medical Center, Leiden, the Netherlands, ³⁹¹Department of Internal Medicine, Division of
 623 Endocrinology, Leiden University Medical Center, Leiden, the Netherlands, ³⁹²Eindhoven

624 Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden,
 625 the Netherlands, ³⁹³Department of Human Genetics, Leiden University Medical Center,
 626 Leiden, the Netherlands, ³⁹⁴Population Health Research Institute, St George's, University of
 627 London, London SW17 0RE, UK, ³⁹⁵National Heart and Lung Institute, Imperial College
 628 London, London, W2 1PG, UK, ³⁹⁶School of Public Health, Imperial College London,
 629 London, W12 7RH, UK, ³⁹⁷Taichung Veterans General Hospital, Taichung, Taiwan; No. 1650,
 630 Sec. 4, Taiwan Boulevard, Xitun District Taichung City 40705, Taiwan, ³⁹⁸Division of
 631 Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital,
 632 Taipei, Taiwan; No. 201, Sec. 2, Shipai Road, Beitou District, Taipei City, 112201, Taiwan,
 633 ³⁹⁹OCDEM, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK, ⁴⁰⁰NIHR Oxford
 634 Biomedical Research Centre, Churchill Hospital, Oxford, UK, ⁴⁰¹Ocular Epidemiology,
 635 Singapore Eye Research Institute, Singapore National Eye Centre, 168751, Singapore,
 636 ⁴⁰²Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS
 637 Medical School, 169857, Singapore, ⁴⁰³Data Science, Singapore Eye Research Institute,
 638 Singapore National Eye Centre, 168751, Singapore, ⁴⁰⁴DZHK (German Centre for
 639 Cardiovascular Research), Munich Heart Alliance partner site, Munich, Germany, ⁴⁰⁵German
 640 Center for Diabetes Research (DZD), Neuherberg, Germany, ⁴⁰⁶University of Exeter Medical
 641 School, University of Exeter, Exeter, EX2 5DW, UK, ⁴⁰⁷Department of Medical Epidemiology
 642 and Biostatistics, Karolinska Institutet, Stockholm, Sweden, ⁴⁰⁸Amsterdam Public Health
 643 research institute, Amsterdam UMC, the Netherlands, ⁴⁰⁹Framingham Heart Study, National
 644 Heart, Lung, and Blood Institute, US National Institutes of Health, Bethesda, MD, USA.,
 645 ⁴¹⁰Department of Genetics, School of Medicine, Mashhad University of Medical Sciences,
 646 Mashhad, Iran, ⁴¹¹Department of Genetics, Shanghai-MOST Key Laboratory of Health and
 647 Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, 201203
 648 China, ⁴¹²Technical University of Munich (TUM) and Klinikum Rechts der Isar, TUM School

649 of Medicine, Munich, Germany, ⁴¹³Department of Public Health, University of Helsinki,
 650 Helsinki, Finland, ⁴¹⁴Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi
 651 Arabia, ⁴¹⁵Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and
 652 Kuopio University Hospital, Finland, ⁴¹⁶Stanford Cardiovascular Institute, Stanford
 653 University, Stanford, CA 94305, USA, ⁴¹⁷Stanford Diabetes Research Center, Stanford
 654 University, Stanford, CA 94305, USA, ⁴¹⁸Department of Medical Sciences, Molecular
 655 Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.,
 656 ⁴¹⁹Regeneron Pharmaceuticals, Tarrytown, NY, USA, ⁴²⁰Lee Kong Chian School of Medicine,
 657 Nanyang Technological University, Singapore 308232, Singapore, ⁴²¹Imperial College
 658 Healthcare NHS Trust, Imperial College London, London W12 0HS, UK, ⁴²²MRC-PHE
 659 Centre for Environment and Health, Imperial College London, London W2 1PG, UK,
 660 ⁴²³National Heart and Lung Institute, Imperial College London, London W12 0NN, UK,
 661 ⁴²⁴School of Electrical & Information Engineering, University of the Witwatersrand, South
 662 Africa, ⁴²⁵Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA,
 663 ⁴²⁶Institute for Minority Health Research, University of Illinois College of Medicine, Chicago,
 664 Illinois, USA, ⁴²⁷Department of Biostatistics, Harvard T.H. Chan School of Public Health, 677
 665 Huntington Avenue, Boston, MA, 02115, USA, ⁴²⁸QIMR Berghofer Medical Research
 666 Institute, 300 Herston Road, Brisbane, Queensland 4006, Australia, ⁴²⁹Center for Non-
 667 Communicable Diseases, Karachi, Sindh, Pakistan & Faisalabad Institute of Cardiology,
 668 Faisalabad, Pakistan, ⁴³⁰Department of Medicine, Columbia University Irving Medical Center,
 669 New York, NY, USA, ⁴³¹Department of Cardiology, Columbia University Irving Medical
 670 Center, New York, NY, USA, ⁴³²Big Data Institute, University of Oxford, Oxford OX3 7LF,
 671 UK, ⁴³³National Institute for Health Research Oxford Biomedical Research Centre, Oxford
 672 University Hospitals, Oxford, UK, ⁴³⁴Aberdeen Centre for Health Data Science, 1:042
 673 Polwarth Building School of Medicine, Medical Science and Nutrition University of

674 Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK, ⁴³⁵Division of Population Health and
 675 Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1
 676 9SY, United Kingdom, ⁴³⁶Biomedical and Translational Informatics, Geisinger Health,
 677 Danville, PA 17822, USA, ⁴³⁷Harvard Medical School, Boston, MA 02115, USA, ⁴³⁸School of
 678 Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College
 679 London, London, UK, ⁴³⁹Department of Biomedical Informatics, Vanderbilt University
 680 Medical Center, Nashville, TN, USA, ⁴⁴⁰Departments of Medicine (Medical Genetics) and
 681 Genome Sciences, University of Washington, USA, ⁴⁴¹Center for Autoimmune Genomics and
 682 Etiology, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, OH, USA.,
 683 ⁴⁴²Division of Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine,
 684 Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA,
 685 ⁴⁴³Department of Anthropology, Northwestern University, Evanston, IL 60208, USA, ⁴⁴⁴Center
 686 for Genetic Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL
 687 60611, USA, ⁴⁴⁵HUNT Research Centre, Department of Public Health and Nursing, NTNU,
 688 Norwegian University of Science and Technology, Levanger, 7600 Norway, ⁴⁴⁶Department of
 689 Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, 7600 Norway,
 690 ⁴⁴⁷Department of Endocrinology, St. Olavs Hospital, Trondheim University Hospital,
 691 Trondheim, Norway, ⁴⁴⁸RIKEN Center for Integrative Medical Sciences, Yokohama, Japan,
 692 ⁴⁴⁹Laboratory of Complex Trait Genomics, Department of Computational Biology and
 693 Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo,
 694 Japan, ⁴⁵⁰Laboratory of Statistical Immunology, WPI Immunology Frontier Research Center,
 695 Osaka University, Osaka, Japan, ⁴⁵¹Integrated Frontier Research for Medical Science Division,
 696 Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka,
 697 Japan, ⁴⁵²Division of Molecular Pathology, Institute of Medical Science, The University of
 698 Tokyo, Tokyo, Japan, ⁴⁵³Division of Genome Research, Center for Genome Science, National

699 Institute of Health, Chungcheongbuk-do, South Korea, ⁴⁵⁴Faculty of Medicine, University of
 700 Iceland, Sæmundargötu 2, Reykjavik, 102, Iceland, ⁴⁵⁵VA Boston Healthcare System, Boston,
 701 MA, USA, ⁴⁵⁶VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care
 702 System, Salt Lake City, UT, USA, ⁴⁵⁷University of Massachusetts, Boston, MA, USA,
 703 ⁴⁵⁸Department of Medicine, University of Pennsylvania Perelman School of Medicine,
 704 Philadelphia, PA, USA, ⁴⁵⁹Cardiovascular Institute, Stanford University School of Medicine,
 705 Stanford, California, USA, ⁴⁶⁰Corporal Michael J. Crescenz VA Medical Center, Philadelphia,
 706 PA, USA, ⁴⁶¹Department of Medicine, Brigham Women's Hospital, Boston, MA, USA,
 707 ⁴⁶²Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA,
 708 ⁴⁶³Endocrinology, Boston Childrens Hospital, Boston 02115 MA, USA, ⁴⁶⁴Departments of
 709 Pediatrics and Genetics, Harvard Medical School, Boston, MA, USA, ⁴⁶⁵Center for Genomic
 710 Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts,
 711 USA, ⁴⁶⁶Cardiology Division, Massachusetts General Hospital, Harvard Medical School,
 712 Boston, MA, USA, ⁴⁶⁷Department of Medicine, Massachusetts General Hospital, Harvard
 713 Medical School, Boston, MA, USA, ⁴⁶⁸Cardiovascular Research Center and Center for
 714 Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA, ⁴⁶⁹Centre for
 715 Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Division of
 716 Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester,
 717 UK, ⁴⁷⁰Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary
 718 Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia, ⁴⁷¹Department of
 719 Biostatistics, Boston University School of Public Health, Boston, MA, USA, ⁴⁷²Department of
 720 Human Genetics, University of Michigan, Ann Arbor, MI, 48109, USA, ⁴⁷³Department of
 721 Statistics, The Pennsylvania State University, University Park, PA, USA, ⁴⁷⁴Huck Institutes of
 722 the Life Sciences, The Pennsylvania State University, University Park, PA, USA, ⁴⁷⁵VA Palo

723 Alto Health Care System, Palo Alto, CA, USA, ⁴⁷⁶Department of Statistics, Stanford
724 University, Stanford, CA, USA

725 *: Shweta Ramdas, Jonathan Judd, Sarah E Graham, Stavroula Kanoni and Yuxuan Wang
726 contributed equally to this work.

727 Corresponding Authors:

728 Xiang Zhu, PhD

729 Department of Statistics

730 Huck Institutes of the Life Sciences

731 The Pennsylvania State University

732 University Park, PA 16802

733 xiangzhu@psu.edu

734

735 Christopher D Brown, PhD

736 Department of Genetics

737 Perelman School of Medicine

738 University of Pennsylvania

739 Philadelphia PA 19104

740 chrbro@upenn.edu

Summary

A major challenge of genome-wide association studies (GWAS) is to translate phenotypic associations into biological insights. Here, we integrate a large GWAS on blood lipids involving 1.6 million individuals from five ancestries with a wide array of functional genomic datasets to discover regulatory mechanisms underlying lipid associations. We first prioritize lipid-associated genes with expression quantitative trait locus (eQTL) colocalizations, and then add chromatin interaction data to narrow the search for functional genes. Polygenic enrichment analysis across 697 annotations from a host of tissues and cell types confirms the central role of the liver in lipid levels, and highlights the selective enrichment of adipose-specific chromatin marks in high-density lipoprotein cholesterol and triglycerides. Overlapping transcription factor (TF) binding sites with lipid-associated loci identifies TFs relevant in lipid biology. In addition, we present an integrative framework to prioritize causal variants at GWAS loci, producing a comprehensive list of candidate causal genes and variants with multiple layers of functional evidence. We highlight two of the prioritized genes, *CREBRF* and *RRBP1*, which show convergent evidence across functional datasets supporting their roles in lipid biology.

Introduction

Most GWAS findings have not directly led to mechanistic interpretations, largely because approximately 90% of GWAS associations map to non-coding sequences^{1,2}. Mechanistic interpretations in GWAS have proven challenging because the strongest signals identified in GWAS typically contain many variants in strong linkage disequilibrium (LD)³ and functional mechanisms including genes of action are often not clear from GWAS data alone^{4,5}.

Linking trait-associated variants to genome function has emerged as a promising model for mechanistic interpretation of non-coding findings in GWAS. This 'variant-to-function' model is premised on recent observations that non-coding variants often affect a trait of interest through the regulation of genes and processes in trait-relevant cell types or tissues^{2,6}. Implementing this functional model in GWAS has become more feasible as large-scale functional genomic resources, such as epigenomic⁷ and transcriptomic⁸ catalogues, have been systematically generated across a wide range of human cell types and tissues. The integration of functional genomics with GWAS has identified regulatory mechanisms in variants associated with some flagship disorders such as obesity⁹ and schizophrenia¹⁰, yielding important functional insights into the genetic architecture of human complex traits.

The history of the human genetics of lipids mirrors the successes and challenges of GWAS. Increasing sample size and genetic diversity has significantly boosted the power of discovery: the first lipid GWAS in 2008 with 8,816 European-descent individuals identified 29 lipid-associated loci¹¹; the latest study of 1.6 million individuals across five ancestries¹² found 941. Despite the dramatic increase in the number of associations, our biological

understanding of many of these genetic discoveries remains limited. The causal gene has been confidently assigned at only a small fraction of these loci ², and the regulatory mechanism connecting variant to phenotype has been conclusively characterized only for a handful of genes ⁵. Furthermore, systematic mapping of lipid-associated variants to their biological functions has been missing in the literature at the time of this study.

Here we conduct a genome-scale integrative analysis on the largest published GWAS to-date of five lipid phenotypes (LDL, or low density lipoprotein; HDL, or high density lipoprotein; TC, or total cholesterol; nonHDL, or non-high density lipoprotein; and TG, or triglycerides) involving 1.65 million individuals from five ancestries ¹². Combining the lipid GWAS with a wide array of functional genomic resources in diverse human tissues and cell types, we identify regulatory mechanisms of noncoding genetic variation in lipids with a full suite of computational approaches. Further, we develop a generalizable framework to understand how tissue-specific gene regulation can explain GWAS findings, and demonstrate its real-world value on lipid-associated loci.

Material and methods

GWAS

We used the recently-published GWAS data for five blood lipid traits (LDL, HDL, TC, TG, and nonHDL) in 1.65 million individuals from five ancestry groups ¹² (African and African-admixed, East Asian, European, Hispanic, South Asian) at 91 million variants imputed primarily from the Haplotype Reference Consortium ¹³ or 1000 Genomes Phase 3 ¹⁴. GWAS

of individual cohorts were based on the hg19 version of the human reference genome. MR-MEGA¹⁵ was used for meta-analysis across cohorts.

We defined 'sentinel variants' as the most significant variant at independent trait-associated loci in the genome. The windows are the greater of 500kb or 0.25cM around the sentinel variant; genetic distances were defined using reference maps from HapMap 3¹⁶. We performed a second round of conditional analysis, conditioning on the sentinel variants to identify and remove any significant windows that are shadow signals of (or dependent on) a neighboring locus to enforce independence of associated loci.

For each sentinel variant, we defined credible sets of potentially causal variants within +/- 500kb region around the sentinel variant representing the set of variants harboring the causal variant with a 95% posterior probability. Full details of the credible set construction are reported in our recent GWAS publication¹². The credible sets are freely available (Web resources).

Colocalization of GWAS associations with eQTLs

We performed statistical colocalization of lipid GWAS with eQTLs obtained from GTEx v8 across 49 tissues⁸. For each of the five lipid traits, we used the same sentinel variants defined in the previous section to represent approximately independent GWAS-associated windows (also removing shadow signals as described before). For each such window, we ran eQTL colocalization with GTEx v8 single-tissue cis-eQTL summary statistics⁸. For each of 49 GTEx tissues, we first identified all genes within 1Mb of the sentinel SNP, and then restricted analysis to those genes with significant eQTLs (i.e., 'eGenes' as defined by GTEx) in that

tissue ($\text{FDR} < 0.05$). We used the R package 'coloc' (R version 3.4.3, coloc version 3.2.1) ¹⁷ with default parameters to run colocalization between the GWAS signal and the eQTL signal for each of these cis-eGenes, using as input those SNPs in the defined window (greater than 500kb or 0.25cM on either side of the lead variant) that are present in both datasets. eQTL summary statistics were in GRCh38, so we lifted over the GWAS summary statistics from hg19 to GRCh38 using liftOver ¹⁸. As in previous studies ¹⁹, we used a colocalization posterior probability of $(\text{PP3} + \text{PP4}) > 0.8$ to identify loci with enough colocalization power, and $\text{PP4} / \text{PP3} > 0.9$ to define those loci that show significant colocalization, where PP4 represents posterior probability of a single shared signal, and PP3 represents posterior probability of two unique signals in the GWAS and eQTL datasets.

Overlap with promoter Capture-C data

We used four promoter-focused Capture-C (henceforth Capture-C) datasets from three human cell types (Web resources) to capture physical interactions between gene promoters and their regulatory elements. The four Capture-C datasets are (1) three biological replicates of HepG2 liver carcinoma cells (HepG2.1) ²⁰; (2) another HepG2 dataset described in Selvarajan et al (HepG2.2) ²¹; (3) hepatocyte-like cells (HLC) produced by differentiating three biological replicates of iPSCs (which in turn were generated from peripheral blood mononuclear cells using a previously published protocol ²²); (4) an adipose dataset obtained from Pan et al ²³ that was produced using primary human white adipocytes. Across the four datasets, the number of significant interactions on the same chromosome ranges from 67,819 (adipose) to 126,565 (HLC). The bait end has a median size of 2,141 (HepG2.1) to 6,567 (HepG2.2) bases. The interacting end has a median size of 2,100 (HepG2.1) to 3,243 base pairs (HepG2.2) for all datasets. The median distance between the bait and interacting ends for all

859 interactions on the same chromosome ranges from 71,722 (HLC) to 285,140 base pairs
860 (adipose).
861
862 The detailed protocol to prepare HepG2 or HLC cells for the Capture-C experiment is
863 described in Chesi et al²⁰. Briefly, for each dataset, 10 million cells were used for promoter
864 Capture-C library generation. Custom capture baits were designed using an Agilent
865 SureSelect library design targeting both ends of DpnII restriction fragments encompassing
866 promoters (including alternative promoters) of all human coding genes, noncoding RNA,
867 antisense RNA, snRNA, miRNA, snoRNA, and lincRNA transcripts, totalling 36,691 RNA
868 baited fragments. Each library was then sequenced on an Illumina HiSeq 4000 (HepG2) or
869 Illumina NovoSeq (HLC), generating 1.6 billion read pairs per sample (50 base pair read
870 length.) We used HiCUP v0.7.2²⁴ to process the raw FASTQ files into loop calls and
871 CHiCAGO v1.6.0²⁵ to define significant looping interactions; we defined a CHiCAGO score
872 of 5 as significant, as specified in the default parameters.
873
874 Starting with Capture-C maps processed as described above, we re-annotated the baits to
875 gene IDs from Gencode v19²⁶ to ensure uniformity of gene annotations with the rest of our
876 pipeline. For each bait, we identified any gene whose transcription start site (TSS) from any
877 transcript in Gencode v19 was within 175 base pair distance from the bait (to account for
878 differing bait designs for external datasets which may not directly overlap the canonical
879 TSS). We filtered all datasets to only include interactions in which the interacting end was
880 not another bait. Enrichment with colocalized genes was robust to our choice of distance
881 between bait and gene (enrichment with eQTL colocalized genes ranging from 2.94-2.96 for
882 bait distances from 0-350 base pairs).

883

To identify genetic variants associated with any of the five lipid traits that physically interact with locations in the genome, we used the R package ‘Genomic Ranges’ version 1.30.3²⁷ to find overlap between credible sets for each trait’s GWAS and the previously annotated promoter Capture-C data. Given the bait end of a gene, we defined a GWAS locus as interacting with this gene if a variant in the credible set for this GWAS locus fell inside the interacting end.

Presence of gene-variant pairs in same topologically associated domains

To assess the frequency of colocalized gene-sentinel variant pairs in the same topologically associated domain (TAD), we used a list of 2,499 publicly-available TADs from human liver²⁸ (Web resources). We computed as a fraction the number of colocalizations with the sentinel variant and colocalized gene in the same TAD divided by all colocalizations in which the sentinel variant lies in a TAD. To test if this fraction was statistically significant, we generated random TAD boundaries using ‘bedtools shuffle’ 1000 times and calculated the same fraction for these randomly-generated TAD boundaries.

Pathway enrichment

We used ClusterProfiler v3.6.0²⁹ to look for pathways over-represented in each gene list: genes with eQTL colocalization and genes interacting with variants in GWAS credible sets. We used the enrichKEGG function to look for enriched pathways in the latest version of the KEGG database³⁰. We first re-mapped gencode IDs to gene symbols using the Gencode v24 annotation and then used the biomaRt R package v2.34.2³¹ to convert gene symbols to

908 Entrez IDs. We ran enrichKEGG to identify enriched pathways that were significant at a
909 Benjamini-Hochberg threshold of 0.05.

910

911 *Enrichment in known lipid-associated genes*

912

913 We calculated enrichment odds ratio of genes identified in our analysis with four known sets
914 of lipid-associated genes using the Fisher's exact test (R function 'fisher.test'). First, we
915 identified 33 Mendelian genes from ClinVar³² with lipidemia-associated ICD10 codes (E78).
916 Second, we used 35 genes with rare-coding variants associated with lipid levels³³. Third, we
917 extracted 1,115 genes associated with 'cholesterol' or 'lipidemia' phenotypes in mouse
918 knockouts from the Mouse Genome Informatics database³⁴. Fourth, we identified 4,008
919 genes from a transcriptome-wide association study (TWAS) on the same GWAS and GTEx
920 v8 summary statistics using the S-PrediXcan software³⁵ default setup. The TWAS method
921 accounts for allelic heterogeneity and thus complements the eQTL colocalization approach
922 that assumes one causal variant per locus.

923

924 *TF binding sites*

925

926 We extracted TF binding sites from ChIP-seq data of 161 TFs in 91 cell types from the
927 ENCODE project⁷ (Web resources). We included all cell types in our primary analysis
928 because TFs were not comprehensively assayed in most cell lines. We also performed a
929 secondary analysis using TF binding sites from HepG2 only. All TF binding sites were
930 aligned to the hg19 version of human reference genome
931 (https://www.encodeproject.org/chip-seq/transcription_factor/).

932

933 *Stratified LD score (S-LDSC) regression analysis*

934

935 We used LDSC version 1.0.1 ³⁶ to estimate the enrichment of heritability explained using
936 GWAS summary statistics in different epigenetic and transcriptomic annotations, including
937 gene expression, chromatin marks, and TF binding sites. The gene expression and chromatin
938 mark annotations across 205 datasets from more than 170 tissues and cell types and the
939 corresponding LD scores were provided as 'Multitissuegeneexpr1000Gv3' and
940 'Multitissuechromatin1000Gv3' databases in LDSC software (Web resources). The LD
941 scores for binding sites of each TF were estimated from 1000 Genomes Phase 3 European
942 samples using 'ldsc.py --l2'. We first converted the summary statistics for each phenotype to
943 LDSC-formatted summary statistics using 'munge_sumstats.py'. Second, we ran 'ldsc.py'
944 using the baseline_v1.2 baseline model on each annotation to estimate enrichment of
945 heritability. For primary analyses, we used multi-ancestry GWAS summary statistics and LD
946 scores estimated from 1000 Genomes Phase 3 European samples. For secondary analyses on
947 East Asian (EAS) GWAS alone, we obtained EAS-specific LD scores for the same functional
948 annotations ³⁷.

949

950 *Genomic regulatory elements and GWAS overlap algorithm (GREGOR) analysis*

951

952 We used GREGOR ³⁸ to estimate enrichment of sentinel variants for each lipid phenotype in
953 TF binding sites for 161 TFs from ENCODE compared to a null distribution of variants
954 matched for allele frequency. We ran GREGOR with default parameters, specifying 0.8 as
955 the R^2 threshold, window size of 1Mb, and 'EUR' as the population. Annotations with
956 enrichment > 2 and FDR-adjusted P-value < 0.05 were considered significant.

957

Enrichment in single-cell expression data

We overlapped our list of colocalized genes with publicly available single-cell RNA-sequencing data of 8,444 cells from liver³⁹ and 38,408 cells from adipose (Web resources) in humans. For both datasets, we downloaded normalized TPM data and existing tSNE cluster annotations for each cell. For each cluster, we defined median expression for each gene across all cells in that cluster. Then for each cluster, we quantified the overrepresentation of our gene list in ranked genes for this cluster via an enrichment P-value computed by the ‘fgsea’⁴⁰ R package v1.4.1 implemented in R 3.4.3.

Results

We systematically integrated lipid GWAS results¹² with multiple layers of functional genomic data from diverse tissues and cell types to understand regulatory mechanisms at lipid-associated loci (Figure 1). Specifically, we overlaid GWAS loci with eQTL and chromatin-chromatin interactions to identify causal genes. We assessed polygenic enrichments of tissue-specific histone marks to prioritize relevant tissues and examined GWAS loci at transcription factor (TF) binding sites to detect lipid-relevant TFs. Finally, we combined all these layers to prioritize functional variants at GWAS loci, providing a holistic view of gene regulation at lipid loci in relevant tissue and cell types.

Colocalization with eQTLs identifies candidate lipid-relevant genes

First, we identified shared association signals between lipid levels and expression of nearby genes, since most GWAS signals are presumed to influence complex traits through impact on

gene expression⁴¹. To do so, we tested for colocalization of each significant lipid GWAS signal with significant cis-eQTL data across 49 human tissues from the GTEx consortium⁸. The significant GWAS signals were 1,750 loci reaching genome-wide significance and corrected for shadow signals in our multi-ancestry meta-analysis for at least one of five lipid traits. Credible set sizes ranged from 1 to 417 variants at the 1,750 examined loci, with a median size of 5 variants per credible set.

Second, we restricted our analysis to loci most likely mediated through regulatory mechanisms as opposed to coding variation. Specifically, we excluded all loci with credible sets containing at least one missense variant (369 of 1,750 loci, 21% of credible sets). Of the remaining 1,381 GWAS loci, 696 significantly colocalized with eQTLs (the ratio of posterior probability of a shared signal to the posterior probability of two signals being > 0.9 ¹⁹) in at least one of 49 tissues for at least one lipid phenotype. This resulted in 1,076 colocalized eGenes ranging from 1 to 16 genes per locus (Figure 2A, Table S1). Since with eQTL data alone it is difficult to disentangle a single functional gene from multiple functional (and likely coregulated) genes at a locus⁴² we performed all downstream analyses with all 1,076 colocalized genes, to further prioritize functional genes at loci with multiple eGenes.

Since lipid-associated genetic variants are often enriched in the liver and adipose^{43,44}, we repeated the colocalization analysis on eQTLs only from liver or adipose. Compared to the 1,076 colocalized eGenes identified from all 49 tissues, the liver- and adipose-only analysis identified 119 and 225 respectively (Figure 2A). The reduced discovery of colocalized eGenes in the liver- and adipose-only analysis is likely due to the small sample sizes of liver (N=208) and adipose (N=581) in GTEx v8 (Figure S1). Leveraging the large degree of tissue sharing in eQTLs^{19,45}, our cross-tissue colocalization analysis enhanced the discovery power

through the collectively large sample size across all 49 tissues (N=15,201). For example, several well-documented lipid-relevant genes such as *PPARA*⁴⁶ and *LPL*⁴⁷ were not identified in the liver- or adipose-only analysis but were identified as significant in our cross-tissue analysis.

To acquire additional functional insights into the 1,076 colocalized genes, we assessed their enrichments across existing biological and clinical gene sets (Figure 2B, Table S2, Table S3). Colocalized genes showed enrichments in (a) 20 KEGG pathways³⁰ at FDR 5%, including known lipid-related processes such as cholesterol metabolism, PPAR signaling, and bile secretion; (b) 33 Mendelian genes from ClinVar³² associated with lipid-related ICD10 codes (11.61-fold enrichment, P=2.08e-06, including *APOB*, *LPL*, and *APOE*), suggesting the shared genetic basis of Mendelian and complex lipid phenotypes⁴⁸; (c) 35 genes with rare-variant burden for lipid phenotypes in a recent multi-ancestry analysis³³ (30.82-fold enrichment, P=1.77e-16, including *APOB*, *LPL*, *LIPG* and *ANGPTL4*), confirming shared mechanisms of rare and common variation underlying lipid traits^{48,49}; (d) genes implicated by cholesterol or lipidemia phenotypes in mouse knockouts (3.92-fold enrichment, P=2.18e-20), suggesting the shared genetic basis of lipid traits between human and mouse⁵⁰. Colocalized genes also showed enrichment with genes implicated in TWAS (Table S4) run on the same GWAS and eQTL summary statistics (20.14-fold enrichment, P<2.22e-308). These enrichment results demonstrate the biological relevance of candidate functional genes prioritized by our approach.

Chromatin-chromatin interactions shortlist eQTL-based colocalization

Our eQTL-based colocalization analysis uses a linear sequence of DNA, and ignores physical interaction between non-adjacent DNA segments, another regulatory layer underlying complex human traits ⁵¹. To add this layer to our analysis, we generated Capture-C data from HepG2 liver carcinoma cells (HepG2.1) and hepatocyte-like cells (HLC) derived from differentiating iPSCs²², as well as publicly-available Capture-C datasets from HepG2 ²¹ (HepG2.2) and white adipocytes ²³. Based on the Capture-C data, we defined an interaction between a GWAS locus and a gene as a significant interaction between the bait end (promoter) for this gene and the interacting end that contains a variant in the credible set for this GWAS locus. In total, 1,079 of 1,750 GWAS loci had at least one variant in the credible set with a physical interaction with a gene promoter and 3,543 of 26,621 genes with promoter-interactions had promoters physically interacting with at least one GWAS credible set variant (Figure 2A, Table S5).

Unlike eQTL-colocalized genes, genes interacting with GWAS credible sets were not significantly enriched in lipid-relevant KEGG pathways (Table S2) and lipid-related genes from ClinVar (Figure 2B, Table S3). These genes were significantly enriched in genes with rare-variant lipid associations (5.36-fold enrichment, $P=2.8e-05$), genes with lipid-related mouse knockouts (1.43-fold enrichment, $P=2.8e-04$), and TWAS-prioritized genes (5.05-fold enrichment, $P=2.5e-288$), but their enrichments were consistently lower than enrichments of eQTL-colocalized genes nonetheless (Figure 2B, Table S3).

Since genes expressed in the liver are most likely to harbour genuine lipid-relevant variant-gene interactions, we repeated the enrichment analyses above restricting both eQTL colocalization and Capture-C interactions to genes expressed in the liver (>0.1 TPM and ≥ 6 reads in at least 20% of GTEx liver samples). Reassuringly, we observed higher enrichments

for each combination of two methods (eQTL, Capture-C) and four databases (ClinVar, Rare Variant, Mouse Knockout, TWAS), when we restricted our analyses to genes expressed in the liver (Figure 2B, Table S3). For the same database, we observed higher enrichments in eQTL colocalized genes than Capture-C prioritized genes, consistent with the results based on all genes.

Genes physically interacting with GWAS loci significantly overlapped with eQTL colocalized genes despite their reduced enrichments in lipid-related gene sets. Of 1,079 credible sets with promoter interactions, 224 also colocalized with eQTLs for the same gene. Across 49 eQTL tissues and four Capture-C cell lines, 233 genes were implicated in both eQTL colocalizations and Capture-C interactions (, Table S6), representing an enrichment of 3-fold compared to random chance (Figure 2C, $P = 3.11 \times 10^{-38}$). Because our Capture-C data came from liver and adipose only, we observed a stronger enrichment in overlap when restricting genes expressed in the liver or adipose (4.5-fold enrichment, $P = 2.89 \times 10^{-65}$). We observed similar enrichment patterns when analysing liver and adipose Capture-C data separately (Figure 2C). Together, the enrichments in overlap suggest that, despite a large number of genes identified by Capture-C (Figure 2A), many of them are likely to harbour functional interactions with GWAS loci.

Chromatin-chromatin interactions helped shortlist functional genes from eQTL colocalization. Among 224 loci with concordant eQTL colocalizations and Capture-C interactions across all tissues, only 39% (88) mapped to a single gene using eQTL data alone, whereas adding Capture-C information increased this fraction to 80% (180). We observed the same trend in the adipose-only and liver-only analysis: 80% (12/15) and 79% (26/33) of loci mapped to a single gene using adipose and liver eQTLs alone, compared to 93% (14/15) and

97% (32/33) after the integration of adipose-only and liver-only Capture-C data respectively (Figure 2D). These results showcase the potential value of combining eQTLs with physical chromatin interactions to prioritize functional genes at GWAS loci.

Since eQTLs are likely to reside in the same topologically associated domain (TAD) as the genes they regulate⁵², we examined TADs from an independent human liver dataset²⁸ at lipid GWAS loci with eQTL colocalizations to confirm GWAS variant-target gene colocalization within the same TAD. Of eQTL-GWAS colocalizations in which the sentinel variant resided within a TAD, 84.8% (1,040 out of 1,235) had the colocalized gene residing in the same TAD ($P < 0.001$ with 1000 permutations). When we restricted to all colocalizations concordant with Capture-C data in any cell type, 96.9% (252 out of 260) of gene-variant pairs fell in the same TAD. This fraction further increased to 100% (33 out of 33) when we repeated the analysis using liver eQTLs and liver Capture-C interactions only. These results add to the existing evidence for TAD boundaries being regulatory insulators in the cell⁵³ and confirm our integration of chromatin interactions with eQTL colocalizations as an effective strategy to hone in on functional genes.

Tissue-specific enrichment of GWAS signals differentiates lipid traits

Regulatory variants often affect complex traits in a tissue-specific manner⁶, as shown in our eQTL colocalization analysis. Specifically, by computing the ratio of the number of colocalizations in a tissue to eQTL sample size in that tissue, we found that the liver was universally enriched for colocalized eGenes with respect to sample size across all lipid traits whereas adipose was selectively enriched in HDL and TG only (Figure S1). Motivated by

1106 these findings, we leveraged systematic approaches and additional data to identify relevant
 1107 tissues and cell types for each lipid trait.
 1108
 1109 We implemented stratified LD score regression (S-LDSC)³⁶, a polygenic approach not
 1110 restricted to genome-wide significant variants, on tissue-specific transcriptomic and
 1111 epigenomic annotations across 205 datasets from more than 170 tissues and cell types, to
 1112 identify relevant tissues for each lipid trait. Consistent with previous studies^{43,44} and our
 1113 eQTL-based analysis, liver-related tissues (Table S7, Table S8) showed strong enrichments
 1114 across all lipid traits (S-LDSC enrichment p-values ranging from .001 in TG to .0001 in TC),
 1115 for both expression (Figure 3A) and chromatin annotations (Figure 3B). This result was
 1116 confirmed by analysis using two other approaches: DEPICT⁵⁴ (Figure S2, Table S9) and
 1117 RSS-NET⁵⁵ (Table S10). To assess the robustness of our S-LDSC results based on multi-
 1118 ancestry GWAS, we applied S-LDSC to population-specific GWAS in European and East
 1119 Asian ancestry participants together with population-specific LD scores and obtained similar
 1120 results (Table S11, Figure S3, Figure S4).
 1121
 1122 The S-LDSC results also highlighted tissues selectively enriched in certain lipid traits as
 1123 shown in the eQTL-based analysis. The most enriched category for HDL using chromatin
 1124 annotation is ‘Adipose H3K4me3’ (P=7.6e-04); for TG, enrichment in liver-related tissues
 1125 (P=1.2e-03) is similar to enrichment in adipose (P=2.7e-03). For LDL, TC, and non-HDL,
 1126 enrichment P-values for the liver were much more significant than for all other tissues
 1127 including adipose (Figure 3B). We observed the same pattern in S-LDSC results based on
 1128 gene expression (Figure 3A). This finding is consistent with the known influence of adipose
 1129 on plasma HDL levels⁵⁶, and the role of adipose as TG deposits⁵⁷. These results were
 1130 corroborated by eQTL colocalizations stratified by phenotype (Figure S1) and DEPICT

analysis on gene expression⁵⁴ (Figure S2, Table S9). Together, these results confirm the liver as a tissue of action for all five lipid traits, and highlight the additional role of adipose primarily in HDL and TG.

Given the importance of the liver and adipose in modulating lipid levels, we further identified the relevant cell types within these tissues. Using existing single-cell data from adipose and liver³⁹, we performed gene-set enrichment analysis⁵⁸ to identify cell-type clusters enriched for genes with eQTL colocalizations for any lipid trait. Out of 11 identified cell types in 20 clusters in the liver, only hepatocytes were enriched at FDR-adjusted $P < 0.05$ (Figure S5, Table S12), consistent with previous results²¹. In adipose, only adipocyte clusters and macrophage-monocyte clusters showed suggestive enrichment (nominal $P < 0.05$) in colocalized genes (Figure S6, Table S12). Of note, the enrichment in adipocytes was significant when we restricted this analysis to genes that were colocalized with HDL and TG (FDR-corrected $P < 0.05$), consistent with the selective enrichments of adipose in HDL and TG (but not the other lipid traits) from our S-LDSC analysis. Evaluations at cellular resolution are required to understand the cell-type specific mechanisms underlying lipid GWAS loci, but our results could form a useful basis for future studies.

Overlapping GWAS signals with binding sites highlights lipid-relevant TFs

TFs have been implicated as a key mediator of linking genetic variation to complex traits⁵⁹. To understand lipid GWAS in the context of TF activity, we assessed enrichment of genome-wide significant variants at TF binding sites using GREGOR³⁸ and performed polygenic enrichment analysis of TF binding sites using S-LDSC. Because TFs were not

1155 comprehensively assayed in most cell lines (Figure S7), we used all cell types in our primary
1156 analysis presented below.

1157

1158 Using ChIP-Seq data from 161 TFs across 91 cell types from the ENCODE project ⁷, 70.7%
1159 of lipid credible sets overlapped with at least one TF binding site. Using GREGOR ³⁸, we
1160 identified 137 TFs whose binding sites were significantly enriched in GWAS lead SNPs for
1161 at least one lipid phenotype (enrichment > 2; FDR adjusted P-value < 0.05; Figure 4A, Table
1162 S13). We obtained similar results when repeating the GREGOR analysis on TF binding sites
1163 derived from HepG2 only (Table S14). To assess the impact of GWAS power on TF
1164 enrichments, we repeated the GREGOR analysis on the same TF binding sites using a
1165 previous version of lipid GWAS ¹¹, and we identified 54 enriched TFs (Table S15). Between
1166 the two versions of lipid GWAS, the total sample size and number of GWAS loci increased
1167 8.7-fold (from 188,577 to 1,650,000) and 11-fold (from 156 to 1750) respectively, but the
1168 number of enriched TFs only increased 2.5-fold (from 54 to 137), suggesting that the large
1169 number of enriched TFs is unlikely driven by the GWAS power alone.

1170

1171 Among these 137 enriched TFs, 69 of them (50%) showed significant enrichments across all
1172 five lipid phenotypes, suggesting a potential core regulatory circuit shared by all lipid traits
1173 (Figure 4A, Table S13). The TF with the strongest enrichment in all phenotypes was ESRRA
1174 (estrogen-related receptor alpha), a nuclear receptor active in metabolic tissues ⁶⁰; ESRRA
1175 has been implicated in adipogenesis and lipid metabolism, and ESRRA-null mice display an
1176 increase in fat mass and obesity ⁶⁰.

1177

1178 The GREGOR analysis also highlighted 68 TFs significantly enriched in specific subsets of
1179 (but not all five) lipid phenotypes (Figure 4A, Table S13). For example, we found 4 TFs

1180 (FOXM1, PBX3, ZKSCAN1, ZEB1) enriched in HDL and TG only, 4 TFs (EZH2, NFE2,
1181 NFATC1, KDM5A) enriched in HDL only and 11 TFs (FOSL1, IRF3, JUN, MEF2C,
1182 NANOG, PRDM1, RUNX3, SIRT6, SMC3, STAT3, ZNF217) enriched in TG only. Of these
1183 TFs, the central role of ZEB1 in adiposity ⁶¹ and fat cell differentiation has been
1184 demonstrated ⁶². These TF-centric findings corroborate the selective enrichments of adipose
1185 in HDL and TG (but not the other lipid traits) identified in our previous tissue prioritization
1186 analyses.

1187

1188 We also performed polygenic enrichment analysis of TF binding sites using S-LDSC (Figure
1189 4B, Table S16), which differed from GREGOR analysis by looking at not only the genome-
1190 wide significant associations but also the polygenic signal without GWAS P-value cutoff. On
1191 the same 161 ENCODE TFs, this polygenic analysis identified 25 TFs whose binding sites
1192 were significantly enriched in heritability explained (nominal $P < 0.05$) for at least one lipid
1193 phenotype; reassuringly, 24 of 25 TFs were also significant in the GREGOR analysis. As a
1194 sensitivity check, we repeated the analysis on TF binding sites derived from HepG2 only, and
1195 we obtained similar results (Table S17).

1196

1197 Among 24 enriched TFs identified by both GREGOR and S-LDSC identified by both
1198 GREGOR and S-LDSC, eight were significantly enriched in all five lipid traits (CEBPB,
1199 CEBPD, FOXA2, HDAC2, HNF4G, NFYA, RXRA, SP1). RXRA (retinoid X receptor
1200 alpha) is encoded by a colocalized gene (*RXRA*) near a GWAS hit (chr9:137,268,682).
1201 RXRA is a ligand-activated transcription factor that forms heterodimers with other receptors
1202 (including PPARG) and is involved in lipid metabolism ⁶³. Moreover, 145 lipid GWAS loci
1203 overlap RXRA binding peaks, and RXRA binds to the promoters of 26 colocalized genes (18
1204 of which are protein-coding) (Figure 4C, Table S18), suggesting that the GWAS variants

might affect lipids (partially) through affecting the binding activity of RXRA. While *RXR4* has been previously implicated as a GWAS locus ⁶⁴, our study demonstrates its role in lipid biology through its regulatory influence on other lipid-associated genes.

Multi-layer functional integration reveals regulatory mechanisms at GWAS loci

Motivated by our finding that integrating chromatin interaction shortlisted eQTL colocalizations, we further brought together multiple lines of functional evidence at each GWAS locus for mechanistic inference. We started with the list of genes with evidence for both eQTL colocalization and Capture-C interactions in the liver or adipose. We next annotated each variant in the 95% credible set with various indicators of regulatory function, including its open chromatin status in liver ²⁰ or adipose-related cell types ⁶⁵, its proximity to a promoter or an enhancer ⁶⁶, and its RegulomeDB regulation probability ⁶⁷; see Table S19 for the complete list of annotations used. To account for complexities of regulatory mechanisms and limitations of functional datasets, we combined evidence across these datasets to prioritize variants at GWAS loci (Figure 5A). Specifically, we prioritized variants with at least three independent lines of functional evidence (chromatin openness, physically interaction with target genes, and promoter/enhancer status) in the liver or adipose, with at least two being in the same tissue with colocalization with the target gene, and with a RegulomeDB score > 0.5. Applying this simple procedure to lipid GWAS we prioritized 28 candidate loci with the strongest multi-layer evidence, 13 of which point to a single functional variant (Table 1). We have also made the full results of variant prioritization freely available (Web resources). Below we describe two examples to highlight key features of this multi-layer integration framework.

1230 *RRBP1* (ribosomal binding protein 1) could be identified from eQTL colocalization alone,
1231 but our multi-layer integration approach strengthened the conclusion via convergent evidence
1232 from various sources (Figure 5B). The *RRBP1* eQTL signals in the liver colocalize with LDL,
1233 TC, and nonHDL GWAS signals. The credible set at this locus contains a single lead variant
1234 (chr20:17,844,684). The 'T' allele of this lead variant decreases *RRBP1* expression levels and
1235 increases LDL, TC, and nonHDL levels. This lead variant is in open chromatin in HLC and
1236 adipose, and physically interacts with the *RRBP1* promoter (250kb away) in adipose. All
1237 these data consistently point to *RRBP1* as the functional gene underlying this locus. *RRBP1*
1238 specifically tethers the endoplasmic reticulum to the mitochondria in the liver (an interaction
1239 that is enriched in hepatocytes) and regulates very low density lipoprotein levels ⁶⁸. Rare
1240 variants in *RRBP1* are associated with LDL in humans ⁶⁹ and silencing *RRBP1* in liver affects
1241 lipid homeostasis in mice ⁶⁸.

1242
1243 *CREBRF* (CREB3 regulatory factor) further demonstrates the power of our multi-layer
1244 integration framework in prioritizing functional variants (Figure 5C). The eQTL signals of
1245 *CREBRF* colocalized with a GWAS locus for HDL with 30 candidate variants. In contrast,
1246 our multi-layer approach identified a single candidate variant (chr5:172,566,698) at this locus
1247 that physically interacts with the *CREBRF* promoter in adipose and is predicted to be a
1248 regulatory element (RegulomeDB score=0.91). Consistent with the index variant
1249 (chr5:172,591,337), the allele 'A' at this functional variant increased HDL levels and
1250 increased *CREBRF* expression in adipose. Missense variants in *CREBRF* have been linked to
1251 body mass index, and the gene has been linked to obesity risk in Samoans ⁷⁰.

1252

1253 Finally, to compare the power of functional fine-mapping with multi-ancestry fine-mapping,
1254 we applied our prioritization rule to credible sets derived from European-only meta-analysis.

1255 The 111 variants prioritized by our rule described above (including multiple variants in the
1256 same credible set) were all found in the multi-ancestry credible sets, representing a 3.7-fold
1257 enrichment ($P < 1e-04$ based on 10000 permutations randomly sampling variants from the
1258 European-only credible sets). This convergence of complementary approaches to the same
1259 smaller set of fine-mapped variants highlights the power of multi-ancestry datasets as an
1260 approach to narrow in on functional variants.

1261

1262 **Discussion**

1263

1264 Here we integrate the largest multi-ancestry lipid GWAS to date with a wide array of
1265 functional genomic resources to understand how noncoding genetic variation affects lipids
1266 through gene regulation. Specifically, we identify 1,076 genes whose eQTL signals
1267 colocalize with lipid GWAS signals and demonstrate how physical chromatin interaction can
1268 improve standard eQTL-based colocalization. We assess tissue-specific enrichments of lipid
1269 GWAS signals and demonstrate the selective importance of adipose in HDL and triglyceride
1270 biology. We examine binding site enrichments of 161 TFs in lipid GWAS and expand our
1271 understanding of lipid GWAS loci (e.g., *RXR4*) in the context of TF activity. Finally, we
1272 build a simple and interpretable prioritization framework that automatically combines
1273 multiple lines of evidence from orthogonal datasets, pinpointing a single functional variant at
1274 each of 13 lipid-associated loci (e.g., *RRBP1* and *CREBRF*). While there are studies that
1275 interpret lipid GWAS associations^{21,71,72}, the size of our multi-ancestry GWAS and multi-
1276 layer functional integration represent a comprehensive effort and an important step forward in
1277 this direction.

1278

1279 Our multi-layer analysis has two key strengths. First, despite a large array of functional
1280 genomic resources being embedded, our analysis produces results with high consistency. For
1281 example, the selective enrichment of adipose in HDL and TG identified by S-LDSC is
1282 confirmed by our eQTL-based colocalization and TF binding site overlap. Another example
1283 of consistency is the multi-layer prioritization of *RRBPI*, which can be identified from eQTL-
1284 based colocalization alone and it is further validated by chromatin accessibility and
1285 interaction. Such convergent evidence from various sources improves the confidence of our
1286 findings. Second, our analysis highlights that combining multiple layers of regulatory
1287 information can improve sensitivity to prioritize functional genes and variants. For example,
1288 we refined eQTL colocalized genes (1,076) to a smaller set of functional genes (233) through
1289 integration with promoter Capture-C data. Another example of sensitivity is *CREBRF*, where
1290 eQTL-based colocalization implicates 30 candidate variants and adding other regulatory
1291 layers points to a single functional variant. Moving forward, we expect these two features
1292 will serve as useful guidelines for future integrative genomic analyses of other traits.

1293

1294 Our results rely on the breadth and accuracy of functional genomic datasets used in our
1295 analyses. First, unlike our lipid GWAS, current functional datasets⁷³ are limited both in
1296 sample size and ancestral diversity, which can affect discovery and replication of regulatory
1297 mechanisms in diverse populations. Second, some functional datasets are generated at limited
1298 resolution. For example, our colocalizations are based on eQTLs from bulk tissue RNA-seq
1299^{8,74}, which may miss detailed cell types and biological processes in which lipid-associated
1300 SNPs regulate gene expression. Third, some functional datasets are not available across the
1301 full spectrum of human tissues and cell types. One example is that our chromatin-chromatin
1302 interaction analysis only examines a few cell types in two known lipid-related tissues,
1303 producing results that may be biased towards known lipid biology. Another example is that

ENCODE TF ChIP-Seq data are not available in adipose-related cell lines. Fourth, our results are validated computationally but not experimentally. That said, our results provide a high-confidence list of regulatory mechanisms at lipid GWAS loci, forming a useful basis for future experiments. As more comprehensive and accurate functional genomic resources are becoming publicly available in diverse cellular contexts and ancestry groups, the resolution and power of integrative analyses like ours will be markedly increased.

Other limitations of this study stem from computational methods embedded in our framework. First, the colocalization approach ‘coloc’ assumes one causal variant per locus, whereas recent studies suggest extensive allelic heterogeneity⁷⁵ consistent with a model of a milieu of related transcription factors binding within a single locus. Accounting for allelic heterogeneity in summary statistics-based colocalization typically requires modelling multiple correlated SNPs through LD matrix⁷⁶, which is computationally intensive in large-scale analyses derived from many cohorts with diverse ancestries, like the multi-ancestry GWAS examined here. Second, due to restricted access to individual genotypes of 201 cohorts, we cannot produce multi-ancestry LD scores within GLGC but have to use European-based LD scores in all S-LDSC analyses. This approach, though less rigorous in principle, provides robust results in practice (as confirmed by our ancestry-specific analysis), largely because 79% of cohorts in GLGC are of European descent¹². That said, we caution that the same approach might fall short in ancestrally diverse studies with few European individuals⁷⁷. Third, our multi-layer variant prioritization framework is built on a series of simple rules that are easy to implement on large datasets. This approach could possibly be formalized as statistical models (e.g., priors in Bayesian methods⁵⁵), but our approach simplifies computation and allows for scalability of the underlying framework. Despite the

1328 technical limitations, our approach here can serve as a useful benchmark for future
1329 development of methods with improved statistical rigor and computation efficiency.

1330 In summary, mapping noncoding genetic variation of complex traits to biological functions
1331 can benefit greatly from thorough integration of multiple layers of functional genomics, as
1332 demonstrated in the present study. Although tested on lipids only, our integrative framework
1333 is straightforward to implement more broadly on many other phenotypes, yielding functional
1334 insights of heritable traits and diseases in humans.

1335 **Description of supplemental data**

1336 Supplemental data include seven figures and nineteen tables, and study-specific
1337 acknowledgements.

1338 **Declaration of interests**

1339 G.C-P. is currently an employee of 23andMe Inc. M.J.C. is the Chief Scientist for Genomics
1340 England, a UK Government company. B.M.P. serves on the steering committee of the Yale
1341 Open Data Access Project funded by Johnson & Johnson. G.T., A.H., D.F.G., H.H., U.T., and
1342 K.S. are employees of deCODE/Amgen Inc. V.S. has received honoraria for consultations
1343 from Novo Nordisk and Sanofi and has an ongoing research collaboration with Bayer Ltd.
1344 M.M. has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received
1345 honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from
1346 Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk,
1347 Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. M.M. and A.M. are employees of
1348 Genentech and a holders of Roche stock. M.S. receives funding from Pfizer Inc. for a project
1349 unrelated to this work. M.E.K. is employed by SYNLAB MVZ Mannheim GmbH. W.M. has
1350 received grants from Siemens Healthineers, grants and personal fees from Aegerion

1351 Pharmaceuticals, grants and personal fees from AMGEN, grants from Astrazeneca, grants
1352 and personal fees from Sanofi, grants and personal fees from Alexion Pharmaceuticals, grants
1353 and personal fees from BASF, grants and personal fees from Abbott Diagnostics, grants and
1354 personal fees from Numares AG, grants and personal fees from Berlin-Chemie, grants and
1355 personal fees from Akzea Therapeutics, grants from Bayer Vital GmbH , grants from
1356 bestbion dx GmbH, grants from Boehringer Ingelheim Pharma GmbH Co KG, grants from
1357 Immundiagnostik GmbH, grants from Merck Chemicals GmbH, grants from MSD Sharp and
1358 Dohme GmbH, grants from Novartis Pharma GmbH, grants from Olink Proteomics, other
1359 from Synlab Holding Deutschland GmbH, all outside the submitted work. A.V.K. has served
1360 as a consultant to Sanofi, Medicines Company, Maze Pharmaceuticals, Navitor
1361 Pharmaceuticals, Verve Therapeutics, Amgen, and Color Genomics; received speaking fees
1362 from Illumina, the Novartis Institute for Biomedical Research; received sponsored research
1363 agreements from the Novartis Institute for Biomedical Research and IBM Research, and
1364 reports a patent related to a genetic risk predictor (20190017119). S.K. is an employee of
1365 Verve Therapeutics, and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis,
1366 and San Therapeutics. He is a member of the scientific advisory boards for Regeneron
1367 Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli
1368 Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug
1369 Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics,
1370 MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and
1371 treating a person having a predisposition to or afflicted with cardiometabolic disease
1372 (20180010185) and a genetics risk predictor (20190017119). D.K. accepts consulting fees
1373 from Regeneron Pharmaceuticals. D.O.M-K. is a part-time clinical research consultant for
1374 Metabolon, Inc. D.S. has received support from the British Heart Foundation, Pfizer,

1375 Regeneron, Genentech, and Eli Lilly pharmaceuticals. The spouse of C.J.W. is employed by
1376 Regeneron.

1377

1378 **Acknowledgments**

1379 XZ is supported by the Stein Fellowship from Stanford University and Institute for
1380 Computational and Data Sciences Seed Grant from The Pennsylvania State University. CDB
1381 is supported by the NIH (R01-HL133218). Funding for the Global Lipids Genetics Consortium
1382 was provided by the NIH (R01-HL127564). This research was conducted using the UK
1383 Biobank Resource under application number 24460. This research is based on data from the
1384 MVP, Office of Research and Development, Veterans Health Administration, and was
1385 supported by awards 2I01BX003362-03A1 and 1I01BX004821-01A1. This publication does
1386 not represent the views of the Department of Veteran Affairs or the United States Government.
1387 We thank Bethany Klunder for administrative support. Study-specific acknowledgements are
1388 provided in the supplemental information.

1389

1390 **Web resources**

1391 Browser of noncoding variant prioritization: [http://csg.sph.umich.edu/willer/public/glgc-](http://csg.sph.umich.edu/willer/public/glgc-lipids2021/variant_prioritization.html)
1392 [lipids2021/variant_prioritization.html](http://csg.sph.umich.edu/willer/public/glgc-lipids2021/variant_prioritization.html)

1393 GLGC GWAS summary statistics and credible sets:

1394 <http://csg.sph.umich.edu/willer/public/glgc-lipids2021/>

1395 GTEx v8 summary statistics: <https://www.gtexportal.org/home/datasets>

1396 coloc: <https://cran.r-project.org/web/packages/coloc>

1397 liftOver: <https://genome.ucsc.edu/cgi-bin/hgLiftOver>

1398 HepG2 Capture-C data (Chesi et al): [https://www.ebi.ac.uk/arrayexpress/experiments/E-](https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7144/)

1399 MTAB-7144/

1400 HepG2 Capture-C data (Selvarajan et al):

1401 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157306>

1402 Human white adipocyte Capture-C data:

1403 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110619>

1404 HiCUP: <https://www.bioinformatics.babraham.ac.uk/projects/hicup/>

1405 CHiCAGO: <https://www.bioconductor.org/packages/release/bioc/html/Chicago.html>

1406 GenomicRanges: <https://bioconductor.org/packages/release/bioc/html/GenomicRanges.html>

1407 Human liver Hi-C data: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58752>

1408 bedtools: <https://bedtools.readthedocs.io/en/latest/>

1409 ClusterProfiler: <https://guangchuangyu.github.io/clusterProfiler>

1410 biomaRt: <https://bioconductor.org/packages/release/bioc/html/biomaRt.html>

1411 ClinVar: <https://www.ncbi.nlm.nih.gov/clinvar/>

1412 MGI: <http://www.informatics.jax.org/downloads/reports/index.html#pheno>

1413 S-PrediXcan: <https://github.com/hakyimlab/MetaXcan>

1414 ENCODE ChIP-Seq data:

1415 <https://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeRegTfbsClustered/>

1416 <wgEncodeRegTfbsClusteredWithCellsV3.bed.gz>

1417 LDSC software: <https://github.com/bulik/ldsc>

1418 European LD scores and related annotations:

1419 <https://data.broadinstitute.org/alkesgroup/LDSCORE/>

1420 East Asian LD scores and related annotations: <http://jenger.riken.jp/en/data>

1421 DEPICT: <https://data.broadinstitute.org/mpg/depict>

1422 RSS-NET: <https://github.com/SUwonglab/rss-net>

1423 Liver single-cell data: <http://shiny.baderlab.org/HumanLiverAtlas/>

1424 Adipose single-cell data:

1425 https://singlecell.broadinstitute.org/single_cell/study/SCP133/human-adipose-svf-single-cell

1426 fgsea: <http://bioconductor.org/packages/release/bioc/html/fgsea.html>

1427 GREGOR: <https://genome.sph.umich.edu/wiki/GREGOR>

1428 Open chromatin data from HepG2: [https://www.omicsdi.org/dataset/arrayexpress-](https://www.omicsdi.org/dataset/arrayexpress-repository/E-MTAB-7543)

1429 [repository/E-MTAB-7543](https://www.omicsdi.org/dataset/arrayexpress-repository/E-MTAB-7543)

1430 Open chromatin data from adipose:

1431 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110734>

1432 Roadmap epigenomic data (promoters and enhancer annotation):
1433 [https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/co](https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/)
1434 [reMarks/jointModel/final/](https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/)

1435 RegulomeDB: <https://regulomedb.org/regulome-search/>

1436

1437 **Data and code availability**

1438 The HLC Capture-C data is available at

1439 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE189026>.

1440 **References**

- 1441 1. Gallagher, M.D., and Chen-Plotkin, A.S. (2018). The Post-GWAS Era: From Association
1442 to Function. *Am. J. Hum. Genet.* *102*, 717–730.
- 1443 2. Cano-Gamez, E., and Trynka, G. (2020). From GWAS to Function: Using Functional
1444 Genomics to Identify the Mechanisms Underlying Complex Diseases. *Front. Genet.* *11*, 424.
- 1445 3. Schaid, D.J., Chen, W., and Larson, N.B. (2018). From genome-wide associations to
1446 candidate causal variants by statistical fine-mapping. *Nat. Rev. Genet.* *19*, 491–504.
- 1447 4. Smemo, S., Tena, J.J., Kim, K.-H., Gamazon, E.R., Sakabe, N.J., Gómez-Marín, C.,
1448 Aneas, I., Credidio, F.L., Sobreira, D.R., Wasserman, N.F., et al. (2014). Obesity-associated
1449 variants within FTO form long-range functional connections with IRX3. *Nature* *507*, 371–375.
- 1450 5. Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N.E., Ahfeldt, T., Sachs, K.V., Li,
1451 X., Li, H., Kuperwasser, N., Ruda, V.M., et al. (2010). From noncoding variant to phenotype
1452 via SORT1 at the 1p13 cholesterol locus. *Nature* *466*, 714–719.
- 1453 6. Hekselman, I., and Yeger-Lotem, E. (2020). Mechanisms of tissue and cell-type specificity
1454 in heritable traits and diseases. *Nat. Rev. Genet.* *21*, 137–150.
- 1455 7. ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements in the
1456 human genome. *Nature* *489*, 57–74.
- 1457 8. The GTEx Consortium (2020). The GTEx Consortium atlas of genetic regulatory effects
1458 across human tissues. *Science* *369*, 1318–1330.
- 1459 9. Loos, R.J.F., and Yeo, G.S.H. (2021). The genetics of obesity: from discovery to biology.
1460 *Nat. Rev. Genet.*
- 1461 10. Huo, Y., Li, S., Liu, J., Li, X., and Luo, X.-J. (2019). Functional genomics reveal gene
1462 regulatory mechanisms underlying schizophrenia risk. *Nat. Commun.* *10*, 1–19.
- 1463 11. Willer, C.J., Sanna, S., Jackson, A.U., Scuteri, A., Bonnycastle, L.L., Clarke, R., Heath,

1464 S.C., Timpson, N.J., Najjar, S.S., Stringham, H.M., et al. (2008). Newly identified loci that
1465 influence lipid concentrations and risk of coronary artery disease. *Nat. Genet.* 40, 161–169.

1466 12. Sarah E Graham, Shoa L Clarke, Kuan-Han H Wu, Stavroula Kanoni, Greg JM Zajac,
1467 Shweta Ramdas, Ida Surakka, Ioanna Ntalla, Sailaja Vedantam,, Thomas W Winkler, Adam
1468 E Locke, Eirini Marouli, Mi Yeong Hwang, Sohee Han, Akira Narita, Ananyo Choudhury,
1469 Amy R Bentley, Kenneth Ekoru, Anurag Verma, Bhavi Trivedi, Hilary C Martin, Karen A
1470 Hunt, Qin Hui,, Derek Klarin,,, Xiang Zhu,,, Gudmar Thorleifsson, Anna Helgadottir, Daniel F
1471 Gudbjartsson,, Hilma Holm, Isleifur Olafsson, Masato Akiyama,, Saori Sakaue,,, Chikashi
1472 Terao, Masahiro Kanai,,, Wei Zhou,,, Ben M Brumpton,,, Humaira Rasheed,, Sanni E
1473 Ruotsalainen, Aki S Havulinna,, Yogasudha Veturi, QiPing Feng, Elisabeth A Rosenthal,
1474 Todd Lingren, Jennifer Allen Pacheco, Sarah A Pendergrass, Jeffrey Haessler, Franco
1475 Giulianini, Yuki Bradford, Jason E Miller, Archie Campbell,, Kuang Lin, Iona Y Millwood,,
1476 George Hindy, Asif Rasheed, Jessica D Faul, Wei Zhao, David R Weir, Constance Turman,
1477 Hongyan Huang, Mariaelisa Graff, Anubha Mahajan#, Michael R Brown, Weihua Zhang,,,
1478 Ketian Yu, Ellen M Schmidt, Anita Pandit, Stefan Gustafsson, Xianying Yin, Jian'an Luan,
1479 Jing-Hua Zhao, Fumihiko Matsuda, Hye-Mi Jang, Kyunghoon Yoon, Carolina Medina-
1480 Gomez,, Achilleas Pitsillides, Jouke Jan Hottenga,, Gonneke Willemsen,, Andrew R Wood,
1481 Yingji Ji, Zishan Gao,,, Simon Haworth,, Ruth E Mitchell,, Jin Fang Chai, Mette Aadahl, Jie
1482 Yao, Ani Manichaikul, Helen R Warren,, Julia Ramirez, Jette Bork-Jensen, Line L Kårhus,
1483 Anuj Goel,, Maria Sabater-Lleal,, Raymond Noordam, Carlo Sidore, Edoardo Fiorillo, Aaron
1484 F McDaid,, Pedro Marques-Vidal, Matthias Wielscher, Stella Trompet,, Naveed Sattar, Line
1485 T Møllehave, Betina H Thuesen, Matthias Munz, Lingyao Zeng,, Jianfeng Huang, Bin Yang,
1486 Alaitz Poveda, Azra Kurbasic, Claudia Lamina, Lukas Forer, Markus Scholz,, Tessel E.
1487 Galesloot, Jonathan P. Bradfield, E Warwick Daw, Joseph M Zmuda, Jonathan S Mitchell,
1488 Christian Fuchsberger, Henry Christensen, Jennifer A Brody, Mary F Feitosa, Mary K
1489 Wojczynski, Michael Preuss, Massimo Mangino,, Paraskevi Christofidou, Niek Verweij, Jan
1490 W Benjamins, Jorgen Engmann,, Rachel L Kember, Roderick C Slieker,, Ken Sin Lo, Nuno
1491 R Zilhao, Phuong Le, Marcus E Kleber,, Graciela E Delgado, Shaofeng Huo, Daisuke D
1492 Ikeda, Hiroyuki Iha, Jian Yang,, Jun Liu, Hampton L Leonard,, Jonathan Marten, Børge
1493 Schmidt, Marina Arendt,, Laura J Smyth, Marisa Cañadas-Garre, Chaolong Wang,,
1494 Masahiro Nakatochi, Andrew Wong, Nina Hutri-Kähönen,, Xueling Sim, Rui Xia, Alicia
1495 Huerta-Chagoya, Juan Carlos Fernandez-Lopez, Valeriya Lyssenko,, Meraj Ahmed, Anne U
1496 Jackson, Marguerite R Irvin, Christopher Oldmeadow, Han-Na Kim, Seungho Ryu,, Paul
1497 RHJ Timmers,, Liubov Arbeeve, Rajkumar Dorajoo, Leslie A Lange, Xiaoran Chai,, Gauri
1498 Prasad,, Laura Lorés-Motta, Marc Pauper, Jirong Long, Xiaohui Li, Elizabeth Theusch,
1499 Fumihiko Takeuchi, Cassandra N Spracklen,, Anu Loukola, Sailalitha Bollepalli, Sophie C
1500 Warner,, Ya Xing Wang, Wen B. Wei, Teresa Nutile, Daniela Ruggiero,, Yun Ju Sung, Yi-
1501 Jen Hung, Shufeng Chen, Fangchao Liu, Jingyun Yang,, Katherine A Kentistou, Mathias
1502 Gorski,, Marco Brumat, Karina Meidtnr,, Lawrence F Bielak, Jennifer A Smith,, Prashantha
1503 Hebbar, Aliko-Eleni Farmaki,, Edith Hofer,, Maoxuan Lin, Chao Xue, Jifeng Zhang, Maria
1504 Pina Concas, Simona Vaccargiu, Peter J van der Most, Niina Pitkänen,, Brian E Cade,,
1505 Jiwon Lee, Sander W. van der Laan, Kumaraswamy Naidu Chitralla, Stefan Weiss, Martina E
1506 Zimmermann, Jong Young Lee, Hyeok Sun Choi, Maria Nethander,, Sandra Freitag-Wolf,
1507 Lorraine Southam,, Nigel W Rayner,,, Carol A Wang, Shih-Yi Lin,,, Jun-Sing Wang,,
1508 Christian Couture, Leo-Pekka Lyytikäinen,, Kjell Nikus,, Gabriel Cuellar-Partida, Henrik
1509 Vestergaard, Bertha Hildalgo, Olga Giannakopoulou, Qiuyin Cai, Morgan O Obura, Jessica
1510 van Setten, Xiaoyin Li, Karen Schwander, Natalie Terzikhan, Jae Hun Shin, Rebecca D
1511 Jackson, Alexander P Reiner, Lisa Warsinger Martin, Zhengming Chen,, Liming Li, Heather
1512 M Highland, Kristin L Young, Takahisa Kawaguchi, Joachim Thiery,, Joshua C Bis, Girish N.
1513 Nadkarni, Lenore J Launer, Huaixing Li, Mike A Nalls,, Olli T Raitakari,,, Sahoko Ichiara,
1514 Sarah H Wild, Christopher P Nelson,, Harry Campbell, Susanne Jäger,, Toru Nabika, Fahd
1515 Al-Mulla, Harri Niinikoski,, Peter S Braund,, Ivana Kolcic, Peter Kovacs, Tota Giardoglou,
1516 Tomohiro Katsuya,, Konain Fatima Bhatti, Dominique de Kleijn, Gert J. de Borst, Eung
1517 Kweon Kim, Hieab H. H. Adams,, M. Arfan Ikram, Xiaofeng Zhu, Folkert W Asselbergs,

1518 Adriaan O Kraaijeveld, Joline WJ Beulens,, Xiao-Ou Shu, Loukianos S Rallidis, Oluf
 1519 Pedersen, Torben Hansen, Paul Mitchell, Alex W Hewitt,, Mika Kähönen,, Louis Pérusse,,
 1520 Claude Bouchard, Anke Tönjes, Yii-Der Ida Chen, Craig E Pennell, Trevor A Mori, Wolfgang
 1521 Lieb, Andre Franke, Claes Ohlsson,, Dan Mellström,, Yoon Shin Cho, Hyejin Lee, Jian-Min
 1522 Yuan,, Woon-Puay Koh,, Sang Youl Rhee, Jeong-Taek Woo, Iris M Heid, Klaus J Stark,
 1523 Henry Völzke, Georg Homuth, Michele K Evans, Alan B Zonderman, Ozren Polasek, Gerard
 1524 Pasterkamp, Imo E Hoefer, Susan Redline,, Katja Pahkala,, Albertine J Oldehinkel, Harold
 1525 Snieder, Ginevra Biino, Reinhold Schmidt, Helena Schmidt, Y Eugene Chen, Stefania
 1526 Bandinelli, George Dedoussis, Thangavel Alphonse Thanaraj, Sharon LR Kardia, Norihiro
 1527 Kato, Matthias B Schulze,, Giorgia Grotto,, Bettina Jung, Carsten A Böger,, Peter K Joshi,
 1528 David A Bennett,, Philip L De Jager,, Xiangfeng Lu, Vasiliki Mamakou,, Morris Brown,, Mark
 1529 J Caulfield,, Patricia B Munroe,, Xiuqing Guo, Marina Ciullo,, Jost B. Jonas,, Nilesh J
 1530 Samani,, Daniel I. Chasman,, Jaakko Kaprio, Päivi Pajukanta, Teresa Tusié-Luna,, Carlos A
 1531 Aguilar-Salinas, Linda S Adair,, Sonny Augustin Bechayda,, H. Janaka de Silva, Ananda R
 1532 Wickremasinghe, Ronald Krauss, Jer-Yuarn Wu, Wei Zheng, Anneke I den Hollander,
 1533 Dwaipayan Bharadwaj,, Adolfo Correa, James G Wilson, Lars Lind, Chew-Kiat Heng,
 1534 Amanda E Nelson,, Yvonne M Golightly,, James F Wilson,, Brenda Penninx,, Hyung-Lae
 1535 Kim, John Attia,, Rodney J Scott,, D C Rao, Donna K Arnett, Mark Walker, Heikki A
 1536 Koistinen,, Giriraj R Chandak,, Chittaranjan S Yajnik, Josep M Mercader,, Teresa Tusie-
 1537 Luna, Carlos Aguilar-Salinas, Clicerio Gonzalez Villalpando, Lorena Orozco, Myriam
 1538 Fornage,, E Shyong Tai,, Rob M van Dam,, Terho Lehtimäki,, Nish Chaturvedi, Mitsuhiro
 1539 Yokota, Jianjun Liu, Dermot F Reilly, Amy Jayne McKnight, Frank Kee, Karl-Heinz Jöckel,
 1540 Mark I McCarthy,, Colin NA Palmer, Veronique Vitart, Caroline Hayward, Eleanor
 1541 Simonsick, Cornelia M van Duijn, Fan Lu, Jia Qu, Haretsugu Hishigaki, Xu Lin, Winfried
 1542 März,, Esteban J Parra, Miguel Cruz, Vilmundur Gudnason,, Jean-Claude Tardif,, Guillaume
 1543 Lettre,, Leen M 't Hart,, Petra JM Elders, Daniel J Rader, Scott M Damrauer,, Meena
 1544 Kumari, Mika Kivimäki, Pim van der Harst, Tim D Spector, Ruth J. F. Loos,, Michael A
 1545 Province, Bruce M Psaty,, Ivan Brandslund,, Peter P Pramstaller, Kaare Christensen, Samuli
 1546 Ripatti,, Elisabeth Widén, Hakon Hakonarson,, Struan F. A. Grant,, Lambertus ALM
 1547 Kiemeny, Jacqueline de Graaf, Markus Loeffler,, Florian Kronenberg, Dongfeng Gu,,
 1548 Jeanette Erdmann, Heribert Schunkert,, Paul W Franks, Allan Linneberg,, J. Wouter
 1549 Jukema,, Amit V Khera,, Minna Männikkö, Marjo-Riitta Jarvelin,, Zoltan Kutalik,, Francesco
 1550 Cucca,, Dennis O Mook-Kanamori,, Ko Willems van Dijk,, Hugh Watkins,, David P
 1551 Strachan, Niels Grarup, Peter Sever, Neil Poulter, Jerome I Rotter, Thomas M Dantoft,
 1552 Fredrik Karpe,, Matt J Neville,, Nicholas J Timpson,, Ching-Yu Cheng,, Tien-Yin Wong,,
 1553 Chiea Chuen Khor, Charumathi Sabanayagam,, Annette Peters,, Christian Gieger,, Andrew
 1554 T Hattersley, Nancy L Pedersen, Patrik KE Magnusson, Dorret I Boomsma,, Eco JC de
 1555 Geus,, L Adrienne Cupples,, Joyce B. J. van Meurs,, Mohsen Ghanbari,, Penny Gordon-
 1556 Larsen,, Wei Huang, Young Jin Kim, Yasuharu Tabara, Nicholas J Wareham, Claudia
 1557 Langenberg, Eleftheria Zeggini,, Johanna Kuusisto, Markku Laakso, Erik Ingelsson,,
 1558 Goncalo Abecasis,, John C Chambers,, Jaspal S Kooner,, Paul S de Vries, Alanna C
 1559 Morrison, Kari E. North, Martha Daviglus, Peter Kraft,, Nicholas G Martin, John B Whitfield,
 1560 Shahid Abbas, Danish Saleheen,, Robin G Walters,, Michael V Holmes,, Corri Black, Blair
 1561 H Smith, Anne E Justice, Aris Baras, Julie E Buring,, Paul M Ridker,, Daniel I Chasman,,
 1562 Charles Kooperberg, Wei-Qi Wei, Gail P Jarvik, Bahram Namjou, M. Geoffrey Hayes,,
 1563 Marylyn D Ritchie, Pekka Jousilahti, Veikko Salomaa, Kristian Hveem,, Bjørn Olav Åsvold,,
 1564 Michiaki Kubo, Yoichiro Kamatani,, Yukinori Okada,, Yoshinori Murakami, Unnur
 1565 Thorsteinsdottir,, Kari Stefansson,, Yuk-Lam Ho, Julie A Lynch,, Daniel Rader, Phil S Tsao,,
 1566 Kyong-Mi Chang,, Kelly Cho,, Christopher J O'Donnell,, John M Gaziano,, Peter Wilson,,
 1567 Charles N Rotimi, Scott Hazelhurst,, Michèle Ramsay,, Richard C Trembath, David A van
 1568 Heel, Gen Tamiya, Masayuki Yamamoto, Bong-Jo Kim, Karen L Mohlke, Timothy M
 1569 Frayling, Joel N Hirschhorn,, Sekar Kathiresan,, VA Million Veteran Program, Global Lipids
 1570 Genetics Consortium, Michael Boehnke, Pradeep Natarajan, Gina M Peloso, Christopher D
 1571 Brown, Andrew P Morris, Themistocles L Assimes, Panos Deloukas, Yan V Sun, Cristen J
 1572 Willer The power of genetic diversity in genome-wide association studies of lipids. Nature.

1573 13. McCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A.R., Teumer, A., Kang,
1574 H.M., Fuchsberger, C., Danecek, P., Sharp, K., et al. (2016). A reference panel of 64,976
1575 haplotypes for genotype imputation. *Nat. Genet.* 48, 1279–1283.

1576 14. 1000 Genomes Project Consortium, and Adam Auton, Lisa D Brooks, Richard M Durbin,
1577 Erik P Garrison, Hyun Min Kang, Jan O Korb, Jonathan L Marchini, Shane McCarthy, Gil A
1578 McVean, Gonalo R Abecasis (2015). A global reference for human genetic variation. *Nature*
1579 526, 68–74.

1580 15. Mgi, R., Horikoshi, M., Sofer, T., Mahajan, A., Kitajima, H., Franceschini, N., McCarthy,
1581 M.I., COGENT-Kidney Consortium, T2D-GENES Consortium, and Morris, A.P. (2017).
1582 Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry
1583 increases power for discovery and improves fine-mapping resolution. *Hum. Mol. Genet.* 26,
1584 3639–3650.

1585 16. The International HapMap 3 Consortium (2010). Integrating common and rare genetic
1586 variation in diverse human populations. *Nature* 467, 52–58.

1587 17. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C.,
1588 and Plagnol, V. (2014). Bayesian test for colocalisation between pairs of genetic association
1589 studies using summary statistics. *PLoS Genet.* 10, e1004383.

1590 18. Kuhn, R.M., Haussler, D., and Kent, W.J. (2013). The UCSC genome browser and
1591 associated tools. *Brief. Bioinform.* 14, 144–161.

1592 19. alıřkan, M., Manduchi, E., Rao, H.S., Segert, J.A., Beltrame, M.H., Trizzino, M., Park,
1593 Y., Baker, S.W., Chesi, A., Johnson, M.E., et al. (2019). Genetic and Epigenetic Fine
1594 Mapping of Complex Trait Associated Loci in the Human Liver. *Am. J. Hum. Genet.* 105, 89–
1595 107.

1596 20. Chesi, A., Wagley, Y., Johnson, M.E., Manduchi, E., Su, C., Lu, S., Leonard, M.E.,
1597 Hodge, K.M., Pippin, J.A., Hankenson, K.D., et al. (2019). Genome-scale Capture C
1598 promoter interactions implicate effector genes at GWAS loci for bone mineral density. *Nat.*
1599 *Commun.* 10, 1260.

1600 21. Selvarajan, I., Toropainen, A., Garske, K.M., Lpez Rodrguez, M., Ko, A., Miao, Z.,
1601 Kaminska, D., unap, K., rd, T., Ravindran, A., et al. (2021). Integrative analysis of liver-
1602 specific non-coding regulatory SNPs associated with the risk of coronary artery disease. *Am.*
1603 *J. Hum. Genet.* 108, 411–430.

1604 22. Pashos, E.E., Park, Y., Wang, X., Raghavan, A., Yang, W., Abbey, D., Peters, D.T.,
1605 Arbelaez, J., Hernandez, M., Kuperwasser, N., et al. (2017). Large, Diverse Population
1606 Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at
1607 Blood Lipid-Associated Loci. *Cell Stem Cell* 20, 558-570.e10.

1608 23. Pan, D.Z., Garske, K.M., Alvarez, M., Bhagat, Y.V., Boockock, J., Nikkola, E., Miao, Z.,
1609 Raulerson, C.K., Cantor, R.M., Civelek, M., et al. (2018). Integration of human adipocyte
1610 chromosomal interactions with adipose gene expression prioritizes obesity-related genes
1611 from GWAS. *Nat. Commun.* 9, 1512.

1612 24. Wingett, S., Ewels, P., Furlan-Magaril, M., Nagano, T., Schoenfelder, S., Fraser, P., and
1613 Andrews, S. (2015). HiCUP: pipeline for mapping and processing Hi-C data. *F1000Res.* 4,
1614 1310.

1615 25. Cairns, J., Freire-Pritchett, P., Wingett, S.W., Vrnai, C., Dimond, A., Plagnol, V.,
1616 Zerbino, D., Schoenfelder, S., Javierre, B.-M., Osborne, C., et al. (2016). CHiCAGO: robust

1617 detection of DNA looping interactions in Capture Hi-C data. *Genome Biol.* 17, 127.

1618 26. Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M., Kokocinski, F.,
1619 Aken, B.L., Barrell, D., Zadissa, A., Searle, S., et al. (2012). GENCODE: the reference
1620 human genome annotation for The ENCODE Project. *Genome Res.* 22, 1760–1774.

1621 27. Lawrence, M., Huber, W., Pagès, H., Aboyoun, P., Carlson, M., Gentleman, R., Morgan,
1622 M.T., and Carey, V.J. (2013). Software for computing and annotating genomic ranges. *PLoS*
1623 *Comput. Biol.* 9, e1003118.

1624 28. Leung, D., Jung, I., Rajagopal, N., Schmitt, A., Selvaraj, S., Lee, A.Y., Yen, C.-A., Lin, S.,
1625 Lin, Y., Qiu, Y., et al. (2015). Integrative analysis of haplotype-resolved epigenomes across
1626 human tissues. *Nature* 518, 350–354.

1627 29. Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R Package for
1628 Comparing Biological Themes Among Gene Clusters. *OMICS: A Journal of Integrative*
1629 *Biology* 16, 284–287.

1630 30. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., and Tanabe, M. (2016). KEGG
1631 as a reference resource for gene and protein annotation. *Nucleic Acids Res.* 44, D457–62.

1632 31. Durinck, S., Spellman, P.T., Birney, E., and Huber, W. (2009). Mapping identifiers for the
1633 integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* 4,
1634 1184–1191.

1635 32. Landrum, M.J., Chitipiralla, S., Brown, G.R., Chen, C., Gu, B., Hart, J., Hoffman, D.,
1636 Jang, W., Kaur, K., Liu, C., et al. (2020). ClinVar: improvements to accessing data. *Nucleic*
1637 *Acids Res.* 48, D835–D844.

1638 33. Hindy, G., Dornbos, P., Chaffin, M.D., Liu, D.J., Wang, M., Selvaraj, M.S., Zhang, D.,
1639 Park, J., Aguilar-Salinas, C.A., Antonacci-Fulton, L., et al. (2022). Rare coding variants in 35
1640 genes associate with circulating lipid levels-A multi-ancestry analysis of 170,000 exomes.
1641 *Am. J. Hum. Genet.* 109, 81–96.

1642 34. Ringwald, M., Richardson, J.E., Baldarelli, R.M., Blake, J.A., Kadin, J.A., Smith, C., and
1643 Bult, C.J. (2022). Mouse Genome Informatics (MGI): latest news from MGD and GXD.
1644 *Mamm. Genome* 33, 4–18.

1645 35. Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, J.M.,
1646 Torstenson, E.S., Shah, K.P., Garcia, T., Edwards, T.L., et al. (2018). Exploring the
1647 phenotypic consequences of tissue specific gene expression variation inferred from GWAS
1648 summary statistics. *Nat. Commun.* 9, 1825.

1649 36. Finucane, H.K., Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-R., Anttila,
1650 V., Xu, H., Zang, C., Farh, K., et al. (2015). Partitioning heritability by functional annotation
1651 using genome-wide association summary statistics. *Nat. Genet.* 47, 1228.

1652 37. Kanai, M., Akiyama, M., Takahashi, A., Matoba, N., Momozawa, Y., Ikeda, M., Iwata, N.,
1653 Ikegawa, S., Hirata, M., Matsuda, K., et al. (2018). Genetic analysis of quantitative traits in
1654 the Japanese population links cell types to complex human diseases. *Nat. Genet.* 50, 390–
1655 400.

1656 38. Schmidt, E.M., Zhang, J., Zhou, W., Chen, J., Mohlke, K.L., Eugene Chen, Y., and
1657 Willer, C.J. (2015). GREGOR: evaluating global enrichment of trait-associated variants in
1658 epigenomic features using a systematic, data-driven approach. *Bioinformatics* 31, 2601–
1659 2606.

1660 39. MacParland, S.A., Liu, J.C., Ma, X.-Z., Innes, B.T., Bartczak, A.M., Gage, B.K., Manuel,
1661 J., Khuu, N., Echeverri, J., Linares, I., et al. (2018). Single cell RNA sequencing of human
1662 liver reveals distinct intrahepatic macrophage populations. *Nat. Commun.* 9, 4383.

1663 40. Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M.N., and Sergushichev, A.
1664 (2021). Fast gene set enrichment analysis. *bioRxiv* 060012; doi:
1665 <https://doi.org/10.1101/060012>

1666 41. Neumeyer, S., Hemani, G., and Zeggini, E. (2020). Strengthening Causal Inference for
1667 Complex Disease Using Molecular Quantitative Trait Loci. *Trends Mol. Med.* 26, 232–241.

1668 42. Y C Loraine Tung, Giles S H Yeo, Stephen O’Rahilly, Anthony P Coll (2014). Obesity
1669 and FTO: Changing Focus at a Complex Locus. *Cell Metab.* 20, 710–718.

1670 43. Hauberg, M.E., Zhang, W., Giambartolomei, C., Franzén, O., Morris, D.L., Vyse, T.J.,
1671 Ruusalepp, A., CommonMind Consortium, Sklar, P., Schadt, E.E., et al. (2017). Large-scale
1672 identification of common trait and disease variants affecting gene expression. *Am. J. Hum.*
1673 *Genet.* 100, 885–894.

1674 44. Boix, C.A., James, B.T., Park, Y.P., Meuleman, W., and Kellis, M. (2021). Regulatory
1675 genomic circuitry of human disease loci by integrative epigenomics. *Nature* 590, 300–307.

1676 45. GTEx Consortium, Laboratory, Data Analysis & Coordinating Center (LDACC)-Analysis
1677 Working Group, Statistical Methods groups-Analysis Working Group, Enhancing GTEx
1678 (eGTEx) groups, NIH Common Fund, NIH/NCI, NIH/NHGRI, NIH/NIMH, NIH/NIDA,
1679 Biospecimen Collection Source Site-NDRI, et al. (2017). Genetic effects on gene expression
1680 across human tissues. *Nature* 550, 204–213.

1681 46. Yoon, M. (2009). The role of PPARalpha in lipid metabolism and obesity: focusing on the
1682 effects of estrogen on PPARalpha actions. *Pharmacol. Res.* 60, 151–159.

1683 47. Wang, H., and Eckel, R.H. (2009). Lipoprotein lipase: from gene to obesity. *Am. J.*
1684 *Physiol. Endocrinol. Metab.* 297, E271–E288.

1685 48. Blair, D.R., Lyttle, C.S., Mortensen, J.M., Bearden, C.F., Jensen, A.B., Khiabani, H.,
1686 Melamed, R., Rabadan, R., Bernstam, E.V., Brunak, S., et al. (2013). A nondegenerate code
1687 of deleterious variants in Mendelian loci contributes to complex disease risk. *Cell* 155,.

1688 49. Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson, A.C., Stylianou, I.M., Koseki,
1689 M., Pirruccello, J.P., Ripatti, S., Chasman, D.I., Willer, C.J., et al. (2010). Biological, clinical
1690 and population relevance of 95 loci for blood lipids. *Nature* 466, 707–713.

1691 50. Brown, S.D.M., Holmes, C.C., Mallon, A.-M., Meehan, T.F., Smedley, D., and Wells, S.
1692 (2018). High-throughput mouse phenomics for characterizing mammalian gene function.
1693 *Nat. Rev. Genet.* 19, 357–370.

1694 51. David U Gorkin, Danny Leung, Bing Ren (2014). The 3D Genome in Transcriptional
1695 Regulation and Pluripotency. *Cell Stem Cell* 14, 762–775.

1696 52. Yu, J., Hu, M., and Li, C. (2019). Joint analyses of multi-tissue Hi-C and eQTL data
1697 demonstrate close spatial proximity between eQTLs and their target genes. *BMC Genet.* 20,
1698 43.

1699 53. Matharu, N.K., and Ahanger, S.H. (2015). Chromatin Insulators and Topological
1700 Domains: Adding New Dimensions to 3D Genome Architecture. *Genes* 6, 790–811.

1701 54. Pers, T.H., Karjalainen, J.M., Chan, Y., Westra, H.-J., Wood, A.R., Yang, J., Lui, J.C.,

1702 Vedantam, S., Gustafsson, S., Esko, T., et al. (2015). Biological interpretation of genome-
1703 wide association studies using predicted gene functions. *Nat. Commun.* 6, 5890.

1704 55. Zhu, X., Duren, Z., and Wong, W.H. (2021). Modeling regulatory network topology
1705 improves genome-wide analyses of complex human traits. *Nat. Commun.* 12, 2851.

1706 56. Zhang, T., Chen, J., Tang, X., Luo, Q., Xu, D., and Yu, B. (2019). Interaction between
1707 adipocytes and high-density lipoprotein: new insights into the mechanism of obesity-induced
1708 dyslipidemia and atherosclerosis. *Lipids Health Dis.* 18, 223.

1709 57. A. D. Sniderman, K. Cianflone, P. Arner, L. K. M. Summers, and K. N. Frayn. (1998).
1710 The Adipocyte, Fatty Acid Trapping, and Atherogenesis. *Arteriosclerosis, Thrombosis, and*
1711 *Vascular Biology.* 18, 147–151.

1712 58. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A.,
1713 Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment
1714 analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
1715 *Proc. Natl. Acad. Sci. U. S. A.* 102, 15545–15550.

1716 59. Degtyareva, A.O., Antontseva, E.V., and Merkulova, T.I. (2021). Regulatory SNPs:
1717 Altered Transcription Factor Binding Sites Implicated in Complex Traits and Diseases. *Int. J.*
1718 *Mol. Sci.* 22,.

1719 60. Tripathi, M., Yen, P.M., and Singh, B.K. (2020). Estrogen-Related Receptor Alpha: An
1720 Under-Appreciated Potential Target for the Treatment of Metabolic Diseases. *Int. J. Mol. Sci.*
1721 21,.

1722 61. Saykally, J.N., Dogan, S., Cleary, M.P., and Sanders, M.M. (2009). The ZEB1
1723 Transcription Factor Is a Novel Repressor of Adiposity in Female Mice. *PLoS One* 4, e8460.

1724 62. Gubelmann, C., Schwalie, P.C., Raghav, S.K., Röder, E., Delessa, T., Kiehlmann, E.,
1725 Waszak, S.M., Corsinotti, A., Udin, G., Holcombe, W., et al. (2014). Identification of the
1726 transcription factor ZEB1 as a central component of the adipogenic gene regulatory network.
1727 *Elife* 3, e03346.

1728 63. Neuschwander-Tetri, B.A. (2015). Retinoid X receptor: the forgotten partner in regulating
1729 lipid metabolism? *Am. J. Clin. Nutr.* 102, 5–6.

1730 64. Peloso, G.M., Demissie, S., Collins, D., Mirel, D.B., Gabriel, S.B., Cupples, L.A., Robins,
1731 S.J., Schaefer, E.J., and Brousseau, M.E. (2010). Common genetic variation in multiple
1732 metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart
1733 disease. *J. Lipid Res.* 51, 3524–3532.

1734 65. Cannon, M.E., Currin, K.W., Young, K.L., Perrin, H.J., Vadlamudi, S., Safi, A., Song, L.,
1735 Wu, Y., Wabitsch, M., Laakso, M., et al. (2019). Open chromatin profiling in adipose tissue
1736 marks genomic regions with functional roles in cardiometabolic traits. *G3 (Bethesda)* 9,
1737 2521–2533.

1738 66. Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M.,
1739 Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015). Integrative
1740 analysis of 111 reference human epigenomes. *Nature* 518, 317–330.

1741 67. Boyle, A.P., Hong, E.L., Hariharan, M., Cheng, Y., Schaub, M.A., Kasowski, M.,
1742 Karczewski, K.J., Park, J., Hitz, B.C., Weng, S., et al. (2012). Annotation of functional
1743 variation in personal genomes using RegulomeDB. *Genome Research* 22, 1790–1797.

1744 68. Anastasia, I., Ilacqua, N., Raimondi, A., Lemieux, P., Ghandehari-Alavijeh, R., Faure, G.,
1745 Mekhedov, S.L., Williams, K.J., Caicci, F., Valle, G., et al. (2021). Mitochondria-rough-ER
1746 contacts in the liver regulate systemic lipid homeostasis. *Cell Rep.* 34, 108873.

1747 69. Jurgens, S.J., Choi, S.H., Morrill, V.N., Chaffin, M., Pirruccello, J.P., Halford, J.L., Weng,
1748 L.-C., Nauffal, V., Roselli, C., Hall, A.W., et al. (2022). Analysis of rare genetic variation
1749 underlying cardiometabolic diseases and traits among 200,000 individuals in the UK
1750 Biobank. *Nat. Genet.* 54, 240–250.

1751 70. Minster, R.L., Hawley, N.L., Su, C.-T., Sun, G., Kershaw, E.E., Cheng, H., Buhule, O.D.,
1752 Lin, J., Reupena, M.S., Viali, S., et al. (2016). A thrifty variant in CREBRF strongly influences
1753 body mass index in Samoans. *Nat. Genet.* 48, 1049–1054.

1754 71. Klarin, D., Damrauer, S.M., Cho, K., Sun, Y.V., Teslovich, T.M., Honerlaw, J., Gagnon,
1755 D.R., DuVall, S.L., Li, J., Peloso, G.M., et al. (2018). Genetics of blood lipids among
1756 ~300,000 multi-ethnic participants of the Million Veteran Program. *Nat. Genet.* 50, 1514–
1757 1523.

1758 72. Li, Z., Votava, J.A., Zajac, G.J.M., Nguyen, J.N., Leyva Jaimes, F.B., Ly, S.M., Brinkman,
1759 J.A., De Giorgi, M., Kaul, S., Green, C.L., et al. (2020). Integrating Mouse and Human
1760 Genetic Data to Move beyond GWAS and Identify Causal Genes in Cholesterol Metabolism.
1761 *Cell Metab.* 31, 741-754.e5.

1762 73. Varshney, A., VanRenterghem, H., Orchard, P., Boyle, A.P., Stitzel, M.L., Ucar, D., and
1763 Parker, S.C.J. (2019). Cell Specificity of Human Regulatory Annotations and Their Genetic
1764 Effects on Gene Expression. *Genetics* 211, 549–562.

1765 74. van der Wijst, M.G.P., de Vries, D.H., Groot, H.E., Trynka, G., Hon, C.C., Bonder, M.J.,
1766 Stegle, O., Nawijn, M.C., Idaghdour, Y., van der Harst, P., et al. (2020). Science Forum: The
1767 single-cell eQTLGen consortium.

1768 75. Arvanitis, M., Tayeb, K., Strober, B.J., and Battle, A. (2022). Redefining tissue specificity
1769 of genetic regulation of gene expression in the presence of allelic heterogeneity. *Am. J.*
1770 *Hum. Genet.* 109, 223–239.

1771 76. Zhu, X., and Stephens, M. (2017). Bayesian large-scale multiple regression with
1772 summary statistics from genome-wide association studies. *Ann. Appl. Stat.* 11, 1561–1592.

1773 77. Wojcik, G.L., Graff, M., Nishimura, K.K., Tao, R., Haessler, J., Gignoux, C.R., Highland,
1774 H.M., Patel, Y.M., Sorokin, E.P., Avery, C.L., et al. (2019). Genetic analyses of diverse
1775 populations improves discovery for complex traits. *Nature* 570, 514–518.

1776

Figure titles and legends

Figure 1. Schematic overview of the multi-layer functional genomic analysis. We integrate GWAS summary statistics for five lipid phenotypes with eQTL and chromatin interaction data to identify potential genes mediating the GWAS loci, and use epigenomic annotations to identify regulatory mechanisms at these loci. For a GWAS locus indexed by a lead variant

‘X’, A, B, and C represent nearby eGenes across tissues, and SNPs around SNP X represent variants in the credible set for this locus.

Figure 2. Overlap between eQTL colocalized genes and Capture-C prioritized genes, and their enrichments in known lipid-associated genes. A. Numbers of genes identified by two approaches: eQTL colocalization and promoter *Capture-C* interaction. Capture-C interactions restricted to genes expressed in the tissue of interest (or in the union of adipose and liver for ‘All Tissues’) are shaded. B. Overlap between two list of prioritized genes (left: Capture-C prioritized genes; right: eQTL colocalized genes) with four external sets of genes previously associated with lipid biology (MGI knockout genes, ClinVar lipidemia-associated genes, genes implicated in rare burden of lipids, and genes from a lipid TWAS). Dashed lines represent enrichments using only genes expressed in the liver. C. Enrichment in overlap between eQTL colocalized genes and Capture-C prioritized genes against what is expected by chance, assuming both gene sets are independent. Dashed lines represent genes expressed in the tissue of interest (or in the union of adipose or liver for ‘All’). Enrichment estimates and confidence intervals shown in Panels B and C are based on the Fisher’s exact test. D. Fraction of colocalized loci that point to a single candidate gene when using eQTL data alone or using both eQTL and Capture-C data.

Figure 3. Tissue relevance of lipid-associated loci. Partitioning heritability of summary statistics on gene expression (A) and active chromatin marks (B) across tissues. Each plotted point represents a tested dataset for enrichment of heritability, with larger dots representing datasets with $P\text{-value} < 0.05$. Each color represents a tissue group (Table S6), and the y-axis represents $-\log_{10} P\text{-value}$ of enrichment of heritability.

Figure 4. TF enrichment identified by GREGOR and S-LDSC. A. Number of TFs enriched in the GREGOR analysis on GWAS loci for each of the five lipid traits. B. Number of TFs enriched in S-LDSC analysis on each of the five lipid traits. C. TF RXRA binds to the promoters of 26 colocalized genes (18 protein-coding); colors represent the subset of lipid phenotypes with colocalization. Larger node sizes represent smaller GWAS P-value of colocalized loci.

Figure 5. Multi-layer functional integration to prioritize variants at GWAS loci. A. Variant annotation and prioritization scheme at each GWAS credible set. B. Evidence for gene *RRBP1* from functional genomics data. The LDL GWAS locus at this region (first row) is an eQTL for gene *RRBP1* in the liver (second row). Variants in the credible set of this locus interact with the gene promoter in both adipose and HepG2 Capture-C data (third row). The interacting variant is also in an open chromatin peak in three liver-related cell types (fourth row). C. Multiple sources of functional genomics data support *CREBRF* as a gene contributing to HDL levels. The HDL GWAS locus at this region (first row) is an eQTL for gene *CREBRF* in adipose (second row). Variants in the credible set at this locus interact with the *CREBRF* promoter in adipose (third row). The interacting variant is also in open chromatin in liver-related cell types (fourth row).

Tables

Table 1. Thirteen prioritized loci with highest confidence of a single functional variant in the credible set. The ‘Sentinel’ column represents the lead variant at the locus. The ‘Prioritized var’ column represents the prioritized variant in the credible set. Columns 5-8 represent overlap of the functional variant with open chromatin (‘Open’), capture-C (‘CapC’) interactions with the candidate gene, enhancer and promoter marks from Roadmap in liver (‘Liver’), adipose (‘Ad’), both or none of these tissues. The ‘RegDB’ column represents the RegulomeDB score of the prioritized variant.

Gene Name	Tissue	Sentinel	Prioritized Var	Open	CapC	Enhancer	Prom-oter	RegDB
<i>CEP68</i>	Adipose	2:65284231	65279414	Liver	Liver	None	Ad	0.5896
<i>TIPARP</i>	Adipose	3:156797941	156795408	Both	Both	Ad	Liver	0.705
<i>CREBRF</i>	Adipose	5:172591337	172566698	Liver	Ad	None	Both	0.9124
<i>PALM2</i>	Adipose	9:112556911	112556911	Both	Ad	Both	None	0.6091
<i>MEGF9</i>	Adipose	9:123481206	123421556	Liver	Ad	None	Liver	0.9933
<i>GBF1</i>	Liver	10:104142294	104107191	Ad	Ad	None	Both	0.705
<i>MICAL2</i>	Liver	11:12071855	12221016	Liver	Liver	None	Liver	0.6018
<i>ACP2</i>	Liver	11:47278917	47276350	Ad	Liver	Liver	Ad	0.6091
<i>PTPRJ</i>	Adipose	11:48021778	48011180	Liver	Ad	Liver	Ad	0.8797
<i>NFATC2IP</i>	Adipose	16:28899411	28883327	Liver	Liver	None	Both	0.6091
<i>HELZ</i>	Liver	17:65109591	65156919	Liver	Liver	None	Both	0.60906
<i>FAM210A</i>	Liver	18:13725674	13725674	Liver	Liver	None	Both	0.7571
<i>RRBP1</i>	Liver	20:17844684	17844684	Both	Ad	Both	None	0.6091